<html class="turbolinks-progress-bar"><head><meta content="width=device-width, initial-scale=1, shrink-to-fit=no" name="viewport"><meta content="text/html; charset=UTF-8" http-equiv="Content-Type"><meta content="fdhmwDBTGwNPe0lKcJVly7AToLfZYvJ-mtjFAPTMZGs" name="google-site-verification"><meta content="296E0FF6379AE64A0D18C39BB40ECD6E" name="msvalidate.01"><meta content="DB01079" name="dc.identifier"><meta content="Tegaserod" name="dc.title"><meta content="Tegaserod is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of constipation predominant irritable bowel syndrome (IBS-C) specifically in women under the age of 65. There is currently no safety or efficacy data for use of tegaserol in men." name="description"><link href="https://go.drugbank.com/drugs/DB01079" rel="canonical"><title>Tegaserod: Uses, Interactions, Mechanism of Action | DrugBank Online</title><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-57x57-precomposed.png" sizes="57x57"><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-60x60-precomposed.png" sizes="60x60"><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-72x72-precomposed.png" sizes="72x72"><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-76x76-precomposed.png" sizes="76x76"><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-114x114-precomposed.png" sizes="114x114"><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-120x120-precomposed.png" sizes="120x120"><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-144x144-precomposed.png" sizes="144x144"><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-152x152-precomposed.png" sizes="152x152"><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-180x180-precomposed.png" sizes="180x180"><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-precomposed.png" sizes="57x57"><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon.png" sizes="57x57"><link rel="icon" type="image/png" href="/favicons/favicon-96x96.png" sizes="96x96"><link rel="icon" type="image/png" href="/favicons/favicon-32x32.png" sizes="32x32"><link rel="icon" type="image/png" href="/favicons/favicon-16x16.png" sizes="16x16"><link rel="icon" type="image/png" href="/favicons/favicon.png" sizes="16x16"><link rel="shortcut icon" type="image/x-icon" href="/favicons/favicon.ico"><meta content="#da532c" name="msapplication-TileColor"><meta content="/favicons/mstile-144x144.png" name="msapplication-TileImage"><meta content="#ffffff" name="theme-color"><meta content="DrugBank" name="application-name"><link as="font" crossorigin="" href="/assets/GemeliWeb-Regular-9ccb07b090f3aef673e3b29ba66e2e685ccf3d438e550624d9739f1bd5164cb2.woff2" rel="preload" type="font/woff2"><link as="font" crossorigin="" href="/assets/GemeliWeb-Bold-f344ff98a063f8cb6ac490b132bda4035ecc8984358dfa8d9bd8621fa38744e2.woff2" rel="preload" type="font/woff2"><link as="font" crossorigin="" href="/assets/GemeliWeb-Light-8227f53ee1957ae57cc0c81d1cfecb59238e3fd9d32b1e792432e1f8c81784a1.woff2" rel="preload" type="font/woff2"><link as="style" data-turbolinks-track="true" href="/assets/public_preload-7bb75340a5ff537e87bf7e9a8383724bc35f25c2f2b5d8e411fdd2a4a657bac3.css" media="all" onload="this.onload=null;this.rel='stylesheet'" rel="stylesheet"><noscript><link href="/assets/public_preload-7bb75340a5ff537e87bf7e9a8383724bc35f25c2f2b5d8e411fdd2a4a657bac3.css" media="all" rel="stylesheet" /></noscript><link rel="stylesheet" media="all" href="/assets/public-7ce82bb78ae55836a7f2a53437b0f77072d3139afdc068f210e726c7d69ac96a.css" data-turbolinks-track="true"><script type="text/javascript" async="" src="https://www.googleadservices.com/pagead/conversion_async.js"></script><script type="text/javascript" async="" src="https://snap.licdn.com/li.lms-analytics/insight.min.js"></script><script async="" src="https://e.clarity.ms/s/0.6.32/clarity.js"></script><script src="https://js.hsadspixel.net/fb.js" type="text/javascript" id="hs-ads-pixel-2224137" data-ads-portal-id="2224137" data-ads-env="prod" data-loader="hs-scriptloader" data-hsjs-portal="2224137" data-hsjs-env="prod" data-hsjs-hublet="na1"></script><script src="https://js.hs-analytics.net/analytics/1646930700000/2224137.js" type="text/javascript" id="hs-analytics"></script><script src="https://js.hs-banner.com/2224137.js" type="text/javascript" id="cookieBanner-2224137" data-cookieconsent="ignore" data-hs-ignore="true" data-loader="hs-scriptloader" data-hsjs-portal="2224137" data-hsjs-env="prod" data-hsjs-hublet="na1"></script><script async="" src="//www.google-analytics.com/analytics.js"></script><script async="" src="https://www.clarity.ms/tag/5600r08mxy"></script><script src="/assets/public-de346f4079123b7b086ddbb3dacbeacd104b373dfb9a9b48e26fc885e64a13ac.js" media="all" data-turbolinks-track="true" defer="defer"></script><script>(function(c,l,a,r,i,t,y){
    c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)};
    t=l.createElement(r);t.async=1;t.src="https://www.clarity.ms/tag/"+i;
    y=l.getElementsByTagName(r)[0];y.parentNode.insertBefore(t,y);
})(window, document, "clarity", "script", "5600r08mxy");</script><meta name="csrf-param" content="authenticity_token">
<meta name="csrf-token" content="5tBMNj7URixGrQUaWeGF9K_0Szve6mqHZxgqO1Tm5KH9JtWB85NV3s1jJC057xcquTjXBuZWn2IYn2eV8zg48w"><style>html.turbolinks-progress-bar::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  z-index: 2000;
  background-color: #0076ff;
  height: 3px;
  opacity: 0.99;
  width: 0%;
  transition: width 300ms ease-out, opacity 150ms ease-in;
  transform: translate3d(0,0,0);
}</style><script async="" src="https://www.googletagmanager.com/gtag/js?id=AW-704543816"></script><script src="https://googleads.g.doubleclick.net/pagead/viewthroughconversion/704543816/?random=1646930944418&amp;cv=9&amp;fst=1646930944418&amp;num=1&amp;bg=ffffff&amp;guid=ON&amp;resp=GooglemKTybQhCsO&amp;u_h=864&amp;u_w=1536&amp;u_ah=816&amp;u_aw=1536&amp;u_cd=24&amp;u_his=27&amp;u_tz=0&amp;u_java=false&amp;u_nplug=5&amp;u_nmime=2&amp;gtm=2oa370&amp;sendb=1&amp;ig=1&amp;data=event%3Dgtag.config&amp;frm=0&amp;url=https%3A%2F%2Fgo.drugbank.com%2Fdrugs%2FDB01079&amp;tiba=Tegaserod%3A%20Uses%2C%20Interactions%2C%20Mechanism%20of%20Action%20%7C%20DrugBank%20Online&amp;hn=www.googleadservices.com&amp;async=1&amp;rfmt=3&amp;fmt=4"></script></head><body class="drugs-c show-a has-banner"><header><nav class="navbar fixed-top navbar-expand-custom navbar-light" id="main-nav" style="background-color: #ff00b8;"><a class="navbar-brand" href="/"><img style="width: 178px; height: 20px;" src="/assets/logo-white-dd185d748ee0164b8ee8f88df29235cd8cfc7936a3c974589262c667e9294219.svg"><div class="online">Online</div></a><button aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation" class="navbar-toggler navbar-toggler-right" data-target="#navbar" data-toggle="collapse" type="button"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbar"><ul class="navbar-nav ml-auto"><li class="nav-item dropdown"><a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#">Browse</a><div class="dropdown-menu"><a class="dropdown-item" href="/drugs"><div class="icon-circle drugbank-icon icon-drugs"><svg class="icon" role="img" title="drugs">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#drugs"></use>
</svg>
</div> Drugs</a><a class="dropdown-item" href="/drugs/starred"><div class="icon-circle drugbank-icon icon-star-fill"><svg class="icon" role="img" title="star-fill">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#star-fill"></use>
</svg>
</div> Starred Drugs</a><a class="dropdown-item" href="/categories"><div class="icon-circle drugbank-icon icon-categories"><svg class="icon" role="img" title="categories">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#categories"></use>
</svg>
</div> Categories</a><a class="dropdown-item" href="/pathways"><div class="icon-circle drugbank-icon icon-pathways"><svg class="icon" role="img" title="pathways">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#pathways"></use>
</svg>
</div> Pathways</a><a class="dropdown-item" href="/reactions"><div class="icon-circle drugbank-icon icon-reactions"><svg class="icon" role="img" title="reactions">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#reactions"></use>
</svg>
</div> Drug Reactions</a><a class="dropdown-item" href="/classyfication"><div class="icon-circle drugbank-icon icon-classifications"><svg class="icon" role="img" title="classifications">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#classifications"></use>
</svg>
</div> Drug Classification</a><a class="dropdown-item" href="/targets"><div class="icon-circle drugbank-icon icon-targets"><svg class="icon" role="img" title="targets">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#targets"></use>
</svg>
</div> Drug Targets</a><div class="dropdown-divider"></div><a class="dropdown-item" href="/pharmaco/genomics"><div class="icon-circle drugbank-icon icon-geno-browse"><svg class="icon" role="img" title="geno-browse">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#geno-browse"></use>
</svg>
</div> Pharmaco-genomics</a><a class="dropdown-item" href="/pharmaco/metabolomics"><div class="icon-circle drugbank-icon icon-chemquery"><svg class="icon" role="img" title="chemquery">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#chemquery"></use>
</svg>
</div> Pharmaco-metabolomics</a><a class="dropdown-item" href="/pharmaco/transcriptomics"><div class="icon-circle drugbank-icon icon-interax"><svg class="icon" role="img" title="interax">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#interax"></use>
</svg>
</div> Pharmaco-transcriptomics</a><a class="dropdown-item" href="/pharmaco/proteomics"><div class="icon-circle drugbank-icon icon-interax"><svg class="icon" role="img" title="interax">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#interax"></use>
</svg>
</div> Pharmaco-proteomics</a></div></li><li class="nav-item dropdown"><a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#">COVID-19</a><div class="dropdown-menu"><a class="dropdown-item" href="/covid-19"><div class="icon-circle drugbank-icon icon-covid-overview"><svg class="icon" role="img" title="covid-overview">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#covid-overview"></use>
</svg>
</div> Overview</a><a class="dropdown-item" href="/covid-19-vaccination"><div class="icon-circle drugbank-icon icon-covid-vaccination"><svg class="icon" role="img" title="covid-vaccination">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#covid-vaccination"></use>
</svg>
</div> Vaccine Side Effects</a></div></li><li class="nav-item dropdown"><a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#">Search</a><div class="dropdown-menu"><a data-no-turbolink="true" class="dropdown-item" href="/structures/search/small_molecule_drugs/structure"><div class="icon-circle drugbank-icon icon-chemquery"><svg class="icon" role="img" title="chemquery">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#chemquery"></use>
</svg>
</div> Chemical Structure</a><a data-no-turbolink="true" class="dropdown-item" href="/structures/search/small_molecule_drugs/mass"><div class="icon-circle drugbank-icon icon-molecular-weight"><svg class="icon" role="img" title="molecular-weight">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#molecular-weight"></use>
</svg>
</div> Molecular Weight</a><a class="dropdown-item" href="/drug-interaction-checker"><div class="icon-circle drugbank-icon icon-interax"><svg class="icon" role="img" title="interax">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#interax"></use>
</svg>
</div> Drug &amp; Food Interactions</a><a class="dropdown-item" data-no-turbolink="true" href="/structures/search/bonds/sequence"><div class="icon-circle drugbank-icon icon-sequence"><svg class="icon" role="img" title="sequence">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#sequence"></use>
</svg>
</div> Target Sequences</a><a class="dropdown-item" data-no-turbolink="true" href="/pharmaco/search"><div class="icon-circle drugbank-icon icon-pathways"><svg class="icon" role="img" title="pathways">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#pathways"></use>
</svg>
</div> Pharmaco-omics</a><a class="dropdown-item" href="/unearth/advanced/drugs"><div class="icon-circle drugbank-icon icon-advanced"><svg class="icon" role="img" title="advanced">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#advanced"></use>
</svg>
</div> Advanced Search</a><div class="dropdown-divider"></div><a class="dropdown-item" href="/spectra/ms/search"><div class="icon-circle drugbank-icon icon-ms"><svg class="icon" role="img" title="ms">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#ms"></use>
</svg>
</div> MS Search</a><a class="dropdown-item" href="/spectra/ms_ms/search"><div class="icon-circle drugbank-icon icon-msms"><svg class="icon" role="img" title="msms">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#msms"></use>
</svg>
</div> MS/MS Search</a><a class="dropdown-item" href="/spectra/c_ms/search"><div class="icon-circle drugbank-icon icon-gcms"><svg class="icon" role="img" title="gcms">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#gcms"></use>
</svg>
</div> GC/MS Search</a><a class="dropdown-item" href="/spectra/nmr_one_d/search"><div class="icon-circle drugbank-icon icon-nmr-1d"><svg class="icon" role="img" title="nmr-1d">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#nmr-1d"></use>
</svg>
</div> 1D NMR Search</a><a class="dropdown-item" href="/spectra/nmr_two_d/search"><div class="icon-circle drugbank-icon icon-nmr-2d"><svg class="icon" role="img" title="nmr-2d">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#nmr-2d"></use>
</svg>
</div> 2D NMR Search</a></div></li><li class="nav-item"><a class="nav-link" href="/drug-interaction-checker">Interaction Checker</a></li><li class="nav-item"><a class="nav-link" href="/releases/latest">Downloads</a></li><li class="nav-item dropdown" role="presentation"><a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#">Solutions</a><div class="dropdown-menu"><div class="link-header dropdown-item">Products</div><div class="link-header dropdown-item blue-header">Commercial Research</div><a class="dropdown-item dropdown-item-last" target="_blank" href="https://www.drugbank.com/datasets"><div class="icon-pink product-icon drugbank-icon icon-scientific"><svg class="icon" role="img" title="scientific"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#scientific"> </use></svg></div> Drug Datasets</a><div class="link-header dropdown-item blue-header">Academic Research</div><a class="dropdown-item dropdown-item-last" target="_blank" href="https://www.drugbank.com/academic_research"><div class="icon-pink product-icon drugbank-icon icon-academic"><svg class="icon" role="img" title="academic"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#academic"> </use></svg></div> Drug Datasets</a><div class="dropdown-divider"></div><a class="dropdown-item dropdown-item-extra-padding" target="_blank" href="https://www.drugbank.com/clinical"><div class="icon-pink product-icon drugbank-icon icon-clinical"><svg class="icon" role="img" title="clinical"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#clinical"> </use></svg></div> Clinical API</a><div class="link-header dropdown-item">Use Cases</div><a class="dropdown-item" target="_blank" href="https://www.drugbank.com/use_cases/ml-drug-discovery-repurposing">Drug Discovery &amp; Repurposing</a><a class="dropdown-item" target="_blank" href="https://www.drugbank.com/use_cases/in-silico-testing"><i>In Silico </i>Testing</a><a class="dropdown-item" target="_blank" href="https://www.drugbank.com/use_cases/precision_medicine">Precision Medicine</a><a class="dropdown-item" target="_blank" href="https://www.drugbank.com/use_cases/telehealth">Telehealth</a><a class="dropdown-item dropdown-item-last" target="_blank" href="https://www.drugbank.com/use_cases/electronic_medical_records">Electronic Medical Records</a><div class="link-header dropdown-item">Resources</div><a class="dropdown-item" target="_blank" href="https://www.drugbank.com/downloads">White Papers</a></div></li><li class="nav-item dropdown"><a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#">About</a><div class="dropdown-menu right-menu"><div class="col-menu"><div class="menu-col"><div class="link-header dropdown-item"><a target="_blank" href="https://dev.drugbank.com/guides/index"><div class=" drugbank-icon icon-help_center"><svg class="icon" role="img" title="help_center"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#help_center"> </use></svg></div> Help Center</a></div><a class="dropdown-item" target="_blank" href="https://dev.drugbank.com/guides/drugbank/citing"><div class="icon-circle drugbank-icon icon-citing"><svg class="icon" role="img" title="citing">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#citing"></use>
</svg>
</div> Citing DrugBank</a><a class="dropdown-item" target="_blank" href="https://dev.drugbank.com/guides/faqs"><div class="icon-circle drugbank-icon icon-faq"><svg class="icon" role="img" title="faq">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#faq"></use>
</svg>
</div> DrugBank Online FAQs</a><a class="dropdown-item" target="_blank" href="https://dev.drugbank.com/guides/drugbank/searching"><div class="icon-circle drugbank-icon icon-search"><svg class="icon" role="img" title="search">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#search"></use>
</svg>
</div> Searching DrugBank</a><a class="dropdown-item" target="_blank" href="https://dev.drugbank.com/guides/drugbank/other_databases"><div class="icon-circle drugbank-icon icon-database"><svg class="icon" role="img" title="database">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#database"></use>
</svg>
</div> Other Databases</a><a class="dropdown-item" target="_blank" href="https://dev.drugbank.com/guides/fields/drugs"><div class="icon-circle drugbank-icon icon-data-sources"><svg class="icon" role="img" title="data-sources">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#data-sources"></use>
</svg>
</div> Data Sources</a></div><div class="menu-col"><div class="link-header dropdown-item"><div class=" drugbank-icon icon-quick_link"><svg class="icon" role="img" title="quick_link"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#quick_link"> </use></svg></div> About</div><a class="dropdown-item" href="/about"><div class="icon-circle drugbank-icon icon-drugbank"><svg class="icon" role="img" title="drugbank">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#drugbank"></use>
</svg>
</div> About DrugBank Online</a><a class="dropdown-item" target="_blank" href="https://dev.drugbank.com/publications"><div class="icon-circle drugbank-icon icon-search"><svg class="icon" role="img" title="search">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#search"></use>
</svg>
</div> DrugBank in Research</a><a class="dropdown-item" href="/stats"><div class="icon-circle drugbank-icon icon-statistics"><svg class="icon" role="img" title="statistics">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#statistics"></use>
</svg>
</div> Statistics</a><a class="dropdown-item" target="_blank" rel="noopener" href="https://blog.drugbank.com/"><div class="icon-circle drugbank-icon icon-news"><svg class="icon" role="img" title="news">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#news"></use>
</svg>
</div> Blog</a><a target="_blank" rel="noopener" class="dropdown-item" href="http://www.wishartlab.com"><div class="icon-circle drugbank-icon icon-wishart"><svg class="icon" role="img" title="wishart">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#wishart"></use>
</svg>
</div> Wishart Research Group</a><a class="dropdown-item" href="/contact"><div class="small-icon icon-circle drugbank-icon icon-paper-plane"><svg class="icon" role="img" title="paper-plane">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#paper-plane"></use>
</svg>
</div> Contact Us</a></div></div></div></li></ul></div></nav><nav class="navbar fixed-top navbar-expand search-bar justify-content-center justify-content-sm-end d-flex"><div class="form-container"><form class="form-inline" action="/unearth/q" accept-charset="UTF-8" method="get"><div class="search-group d-none d-sm-block" style="margin-right: 0.5rem;"><select name="searcher" id="searcher" class="form-control input-md"><option value="drugs">Drugs</option>
<option value="bio_entities">Targets</option>
<option value="pathways">Pathways</option>
<option value="indications">Indications</option></select> <div class="drugbank-icon icon-arrow-down"><svg class="icon" role="img" title="arrow-down">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#arrow-down"></use>
</svg>
</div> </div><div class="search-group"><input type="text" name="query" id="query" class="search-query"> <div class="drugbank-icon icon-search"><svg class="icon" role="img" title="search">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#search"></use>
</svg>
</div> </div></form></div><div class="mini-banner banner-holder"><a target="_blank" href="https://www.drugbank.com/academic_research"><div class="banner-text"><span class="mr-3">Are you in academia? Check out our <b>free datasets</b> for students, professors, &amp; university labs!</span><span class="banner-link"><span>Learn more</span><div class="icon-circle drugbank-icon icon-arrow-right"><svg class="icon" role="img" title="arrow-right">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#arrow-right"></use>
</svg>
</div></span></div></a><div class="close-banner"><div class="drugbank-icon icon-cross"><svg class="icon" role="img" title="cross">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#cross"></use>
</svg>
</div></div></div></nav></header><main role="main"><div class="content-container"><div class="drug-content"><div class="sidebar"><a href="#" id="nav-button"><span>NAV<div class=" toggler"><svg class="hamburger" role="img" title="hamburger" viewBox="0 0 30 20" width="30" height="20"> <use xlink:href="/assets/plus/Mobile_Hamburger-f38f662ee947784bf77c5d4fd6d664e5d38434e2dfa967616cd85abaec045cbc.svg#hamburger"> </use></svg></div></span></a><div class="sidebar-content" style="max-height: 596px;"><div class="sidebar-search"><input type="text" name="sidebar_query" id="sidebar_query" class="search-query"> <div class="drugbank-icon icon-search"><svg class="icon" role="img" title="search">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#search"></use>
</svg>
</div> </div><div class="accordion" id="drug-sidebar"><div class="card"><a class="sidebar-header sidebar-link" id="identification-sidebar-header" href="#identification-header" data-toggle="collapse" data-target="#identification-list">Identification</a><div class="sidebar-list collapse" data-parent="#drug-sidebar" id="identification-list"><a class="sidebar-link" href="#summary">Summary</a><a class="sidebar-link" href="#brand-names">Brand Names</a><a class="sidebar-link" href="#name">Name</a><a class="sidebar-link" href="#accession-number">Accession Number</a><a class="sidebar-link" href="#background">Background</a><a class="sidebar-link" href="#type">Type</a><a class="sidebar-link" href="#groups">Groups</a><a class="sidebar-link" href="#structure">Structure</a><a class="sidebar-link" href="#weight">Weight</a><a class="sidebar-link" href="#chemical-formula">Chemical Formula</a><a class="sidebar-link" href="#synonyms">Synonyms</a><a class="sidebar-link" href="#external-ids">External IDs</a></div></div><div class="card"><a class="sidebar-header sidebar-link" id="pharmacology-sidebar-header" href="#pharmacology-header" data-toggle="collapse" data-target="#pharmacology-list">Pharmacology</a><div class="sidebar-list collapse" data-parent="#drug-sidebar" id="pharmacology-list"><a class="sidebar-link" href="#indication">Indication</a><a class="sidebar-link" href="#associated-conditions">Associated Conditions</a><a class="sidebar-link" href="#contraindications-blackbox-warnings">Contraindications &amp; Blackbox Warnings</a><a class="sidebar-link" href="#pharmacodynamics">Pharmacodynamics</a><a class="sidebar-link" href="#mechanism-of-action">Mechanism of action</a><a class="sidebar-link" href="#absorption">Absorption</a><a class="sidebar-link" href="#volume-of-distribution">Volume of distribution</a><a class="sidebar-link" href="#protein-binding">Protein binding</a><a class="sidebar-link" href="#metabolism">Metabolism</a><a class="sidebar-link" href="#route-of-elimination">Route of elimination</a><a class="sidebar-link" href="#half-life">Half-life</a><a class="sidebar-link" href="#clearance">Clearance</a><a class="sidebar-link" href="#adverse-effects">Adverse Effects</a><a class="sidebar-link" href="#toxicity">Toxicity</a><a class="sidebar-link" href="#pathways">Pathways</a><a class="sidebar-link" href="#pharmacogenomic-effects-adrs">Pharmacogenomic Effects/ADRs</a></div></div><div class="card"><a class="sidebar-header sidebar-link" id="interactions-sidebar-header" href="#interactions-header" data-toggle="collapse" data-target="#interactions-list">Interactions</a><div class="sidebar-list collapse" data-parent="#drug-sidebar" id="interactions-list"><a class="sidebar-link" href="#drug-interactions">Drug Interactions</a><a class="sidebar-link" href="#food-interactions">Food Interactions</a></div></div><div class="card"><a class="sidebar-header sidebar-link" id="products-sidebar-header" href="#products-header" data-toggle="collapse" data-target="#products-list">Products</a><div class="sidebar-list collapse" data-parent="#drug-sidebar" id="products-list"><a class="sidebar-link" href="#product-ingredients">Product Ingredients</a><a class="sidebar-link" href="#international-other-brands">International/Other Brands</a><a class="sidebar-link" href="#brand-name-prescription-products">Brand Name Prescription Products</a></div></div><div class="card"><a class="sidebar-header sidebar-link" id="categories-sidebar-header" href="#categories-header" data-toggle="collapse" data-target="#categories-list">Categories</a><div class="sidebar-list collapse" data-parent="#drug-sidebar" id="categories-list"><a class="sidebar-link" href="#atc-codes">ATC Codes</a><a class="sidebar-link" href="#drug-categories">Drug Categories</a><a class="sidebar-link" href="#chemical-taxonomy">Chemical Taxonomy</a><a class="sidebar-link" href="#affected-organisms">Affected organisms</a></div></div><div class="card"><a class="sidebar-header sidebar-link" id="chemical-identifiers-sidebar-header" href="#chemical-identifiers-header" data-toggle="collapse" data-target="#chemical-identifiers-list">Chemical Identifiers</a><div class="sidebar-list collapse" data-parent="#drug-sidebar" id="chemical-identifiers-list"><a class="sidebar-link" href="#unii">UNII</a><a class="sidebar-link" href="#cas-number">CAS number</a><a class="sidebar-link" href="#inchi-key">InChI Key</a><a class="sidebar-link" href="#inchi">InChI</a><a class="sidebar-link" href="#iupac-name">IUPAC Name</a><a class="sidebar-link" href="#smiles">SMILES</a></div></div><div class="card"><a class="sidebar-header sidebar-link" id="references-sidebar-header" href="#references-header" data-toggle="collapse" data-target="#references-list">References</a><div class="sidebar-list collapse" data-parent="#drug-sidebar" id="references-list"><a class="sidebar-link" href="#synthesis-reference">Synthesis Reference</a><a class="sidebar-link" href="#general-references">General References</a><a class="sidebar-link" href="#external-links">External Links</a><a class="sidebar-link" href="#fda-label">FDA label</a><a class="sidebar-link" href="#msds">MSDS</a></div></div><div class="card"><a class="sidebar-header sidebar-link" id="clinical-trials-sidebar-header" href="#clinical-trials-header" data-toggle="collapse" data-target="#clinical-trials-list">Clinical Trials</a></div><div class="card"><a class="sidebar-header sidebar-link" id="pharmacoeconomics-sidebar-header" href="#pharmacoeconomics-header" data-toggle="collapse" data-target="#pharmacoeconomics-list">Pharmacoeconomics</a><div class="sidebar-list collapse" data-parent="#drug-sidebar" id="pharmacoeconomics-list"><a class="sidebar-link" href="#manufacturers">Manufacturers</a><a class="sidebar-link" href="#packagers">Packagers</a><a class="sidebar-link" href="#dosage-forms">Dosage Forms</a><a class="sidebar-link" href="#prices">Prices</a><a class="sidebar-link" href="#patents">Patents</a></div></div><div class="card"><a class="sidebar-header sidebar-link" id="properties-sidebar-header" href="#properties-header" data-toggle="collapse" data-target="#properties-list">Properties</a><div class="sidebar-list collapse" data-parent="#drug-sidebar" id="properties-list"><a class="sidebar-link" href="#state">State</a><a class="sidebar-link" href="#experimental-properties">Experimental Properties</a><a class="sidebar-link" href="#predicted-properties">Predicted Properties</a><a class="sidebar-link" href="#predicted-admet-features">Predicted ADMET Features</a></div></div><div class="card"><a class="sidebar-header sidebar-link" id="spectra-sidebar-header" href="#spectra-header" data-toggle="collapse" data-target="#spectra-list">Spectra</a><div class="sidebar-list collapse" data-parent="#drug-sidebar" id="spectra-list"><a class="sidebar-link" href="#mass-spec">Mass Spec</a><a class="sidebar-link" href="#spectra">Spectra</a></div></div><div class="card"><a class="sidebar-header sidebar-link" id="targets-sidebar-header" href="#targets">Targets (4)</a></div><div class="card"><a class="sidebar-header sidebar-link" id="enzymes-sidebar-header" href="#enzymes">Enzymes (4)</a></div><div class="card"><a class="sidebar-header sidebar-link" id="transporters-sidebar-header" href="#transporters">Transporters (3)</a></div></div></div></div><div class="drug-card"><div class="content-header d-sm-flex align-items-center"><h1 class="align-self-center mr-4">Tegaserod</h1><div class="page-actions ml-auto justify-content-sm-end mt-2 mt-sm-0"><div class="record-user-actions d-flex"><div class="record-watch-controls" id="record-watch-controls"><div aria-label="Watch an entry" class="btn-group ml-auto" role="group"><div class="btn-group" role="group"><button aria-expanded="false" aria-haspopup="true" class="btn btn-pink-filled dropdown-toggle" data-toggle="dropdown" type="button"><div class="drugbank-icon icon-eye"><svg class="icon" role="img" title="eye">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#eye"></use>
</svg>
</div><strong class="pl-1">Watch</strong></button><div class="dropdown-menu"><a class="dropdown-item" href="/public_users/sign_in?record_watch_accession=DB01079"><div class="button-label" data-placement="left" data-toggle="watch-tooltip" title="You must be signed in to watch an entry">All Activity</div><small class="text-muted">Notified of all changes on this drug.</small></a><a class="dropdown-item" data-toggle="watch-tooltip" href="/public_users/sign_in?record_watch_accession=DB01079" title="You must be signed in to watch an entry"><div class="button-label">Major changes</div><small class="text-muted">Notified of marketing changes.</small></a></div></div><a aria-label="0 readers watchred this entry" class="btn btn-pink" href="#"><strong class="px-2">0</strong></a></div></div><div class="record-star-controls ml-2" id="record-star-controls"><div aria-label="Star an entry" class="btn-group ml-auto" role="group"><a class="btn btn-pink-filled d-flex justify-content-center d-md-table mx-auto" data-placement="left" data-toggle="star-tooltip" href="/public_users/sign_in?record_star_accession=DB01079" title="You must be signed in to star an entry"><div class="drugbank-icon icon-star"><svg class="icon" role="img" title="star">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#star"></use>
</svg>
</div><strong class="pl-1">Star</strong></a><a aria-label="0 readers starred this entry" class="btn btn-pink" href="#"><strong class="px-2">0</strong></a></div></div></div></div></div><div class="card-content px-md-4 px-sm-2 pb-md-4 pb-sm-2"><h2 id="identification-header" class="section-header hidden-header">Identification</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4" id="summary">Summary</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p><strong>Tegaserod</strong> is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of constipation predominant irritable bowel syndrome (IBS-C) specifically in women under the age of 65. There is currently no safety or efficacy data for use of tegaserol in men.</p></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="brand-names">Brand Names</dt><dd class="col-xl-10 col-md-9 col-sm-8"><div class="truncate-overflow show-less"><em class="brand-list">Zelnorm</em><span class="truncate-btn" style="display: none;"></span></div></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="generic-name">Generic Name</dt><dd class="col-xl-4 col-md-9 col-sm-8 pr-xl-2">Tegaserod</dd><dt class="col-xl-2 col-md-3 col-sm-4 pl-xl-2" id="drugbank-accession-number">DrugBank Accession Number</dt><dd class="col-xl-4 col-md-9 col-sm-8">DB01079</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="background">Background</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65" href="#reference-L5918" data-original-title="" title="">5</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup> It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause dangerous cardiovascular events in patients.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65" href="#reference-L5918" data-original-title="" title="">5</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup> Since then, closer evaluations of the original data suggesting such cardiovascular risk have resulted in the limited reintroduction or 're-approval' of tegaserod for treatment of IBS-C specifically in female patients less than 65 years of age and whom are considered to be at a lower risk of a cardiovascular event than the broader population.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65" href="#reference-L5918" data-original-title="" title="">5</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup> Zelnorm (tegaserod) by Sloan Pharma subsequently gained re-approval in April of 2019.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65" href="#reference-L5918" data-original-title="" title="">5</a></sup> Nevertheless, tegaserod remains un-approved in certain regions.<sup class="text-reference-group"><a class="reference-popover-link" data-content="EMA Refusal Assessment Report for Zelnorm (Tegaserod)" href="#reference-F4226" data-original-title="" title="">7</a></sup></p>
<p>Despite the relative complications involved in its history of regulatory approval, ever since its first introduction in 2002 tegaserod remains the only therapy for IBS-C that possesses the unique mechanism of action of acting on serotonin-4 (5-HT(4)) receptors in smooth muscle cells and in the gastrointestinal wall to facilitate actions like esophageal relaxation, peristaltic gut movement, and natural secretions in the gut, among others.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65" href="#reference-L5918" data-original-title="" title="">5</a>,<a class="reference-popover-link" data-content="Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. (PubMed ID 15466450)" href="#reference-A11044" data-original-title="" title="">1</a>,<a class="reference-popover-link" data-content="Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, Sheldrick RL, Carey J, Coleman RA, Baxter GS: 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol. 2002 Mar;135(5):1144-51. doi: 10.1038/sj.bjp.0704571. (PubMed ID 11877320)" href="#reference-A176762" data-original-title="" title="">3</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a>,<a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup></p>
</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="type">Type</dt><dd class="col-xl-4 col-md-9 col-sm-8 pr-xl-2">Small Molecule</dd><dt class="col-xl-2 col-md-3 col-sm-4 pl-xl-2" id="groups">Groups</dt><dd class="col-xl-4 col-md-9 col-sm-8">Approved, Investigational, Withdrawn</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="structure">Structure</dt><dd class="col-xl-4 col-md-9 col-sm-8 pr-xl-2"><div class="structure"><a class="moldbi-vector-thumbnail" href="/structures/DB01079/image.svg"><img src="/structures/DB01079/thumb.svg"></a></div><div class="structure-links"><div class="btn-group btn-group-sm" data-no-turbolink=""><a data-toggle="modal" class="btn btn-outline-secondary" rel="nofollow" href="#structure-zoom"><div class="drugbank-icon icon-zoom-in"><svg class="icon" role="img" title="zoom-in">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#zoom-in"></use>
</svg>
</div></a><div class="btn-group btn-group-sm" id="structure-download"><button aria-expanded="false" aria-haspopup="true" class="btn btn-outline-secondary dropdown-toggle" data-toggle="dropdown" id="structure-download" type="button">Download </button><div aria-labelledby="structure-download" class="dropdown-menu"><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01079.mol">MOL</a><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01079.sdf">SDF</a><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01079.pdb">PDB</a><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01079.smiles">SMILES</a><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01079.inchi">InChI</a></div></div><a class="btn btn-outline-secondary" rel="nofollow" href="/structures/search/small_molecule_drugs/structure?database_id=DB01079&amp;search_type=similarity#results"><div class="drugbank-icon icon-chemquery"><svg class="icon" role="img" title="chemquery">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#chemquery"></use>
</svg>
</div> Similar Structures</a></div><div class="modal fade" id="structure-zoom"><div class="modal-dialog modal-lg" role="document"><div class="modal-content"><div class="modal-header"><h4 class="modal-title">Structure for Tegaserod (DB01079)</h4><button aria-hidden="true" class="close" data-dismiss="modal" type="button"><span aria-hidden="true">×</span></button></div><div class="modal-body"><div class="d-flex justify-content-center"><img src="/structures/DB01079/image.svg"></div></div><div class="modal-footer"><button class="btn btn-default" data-dismiss="modal" type="button"> Close</button></div></div></div></div></div></dd><dl class="right-dl col-xl-6 col-lg-12"><dt class="col-xl-4 col-md-3 col-sm-4 pl-xl-2" id="weight">Weight</dt><dd class="col-xl-8 col-md-9 col-sm-8">Average: 301.394 <br>Monoisotopic: 301.190260381 </dd><dt class="col-xl-4 col-md-3 col-sm-4 pl-xl-2" id="chemical-formula">Chemical Formula</dt><dd class="col-xl-8 col-md-9 col-sm-8">C<sub>16</sub>H<sub>23</sub>N<sub>5</sub>O</dd></dl><dt class="col-xl-2 col-md-3 col-sm-4" id="synonyms">Synonyms<a class="note table-toggle synonyms-toggle" href=""></a></dt><dd class="col-xl-10 col-md-9 col-sm-8 allow-overflow"><ul class="list-unstyled inline-list-break common-synonym-list"><li>1-(((5-Methoxyindol-3-yl)methylene)amino)-3-pentylguanidine</li><li class="common">Tégasérod<div class="language-flag french" title="" data-original-title="French"></div></li><li class="common">Tegaserod<div class="language-flag english" title="" data-original-title="English"></div><div class="language-flag spanish" title="" data-original-title="Spanish"></div></li><li class="common">Tegaserodum<div class="language-flag latin" title="" data-original-title="Latin"></div></li></ul></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="external-ids">External IDs <a tabindex="0" role="button" data-toggle="popover" data-content="Codes and identifiers used by other resources and companies, often used before choosing a marketing name." title="" id="external-identifiers-info" class="drug-info-popup" href="javascript:void(0);" data-original-title="About External Identifiers"><div class="drugbank-icon icon-information"><svg class="icon" role="img" title="information">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#information"></use>
</svg>
</div></a><a class="note table-toggle" href=""><div class="icon-blue drugbank-icon icon-table"><svg class="icon" role="img" title="table">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#table"></use>
</svg>
</div><div class="icon-blue drugbank-icon icon-list"><svg class="icon" role="img" title="list">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#list"></use>
</svg>
</div></a></dt><dd class="col-xl-10 col-md-9 col-sm-8"><ul class="list-unstyled inline-list"><li>HTF 919</li>
<li>HTF-919</li>
<li>SDZ HTF 919</li>
<li>SDZ-HTF-919</li></ul></dd></dl><h2 id="pharmacology-header" class="section-header">Pharmacology</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4" id="indication">Indication</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>Tegaserod is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C) <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. The safety and effectiveness of tegaserod in men with IBS-C have not been established <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>.</p>
<a class="locked-incopy track-link" target="_blank" data-link-id="locked/pharmacology-desktop-2" href="https://bit.ly/3l5TIQu?li=locked/pharmacology-desktop-2"><div class="incopy-left incopy-pharmacology"><img class="locked-pharmacology-img" src="/assets/locked/Pharmacology-fb0b317cceb9ebe868032aa87f450091c78706fb3ea0aad5bc263dda3db7a021.png"><div class="incopy-text pharmacology-text"><div class="title"><strong>Reduce drug development failure rates</strong></div><div class="subtitle"><strong>Build, train, &amp; validate machine-learning models</strong><br>with evidence-based and structured datasets.</div></div></div><div class="incopy-button btn btn-pink-filled">See how<div class=" drugbank-icon icon-see_more"><svg class="icon" role="img" title="see_more"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#see_more"> </use></svg></div></div></a><a class="locked-incopy locked-incopy-mobile track-link" target="_blank" data-link-id="locked/pharmacology-mobile-2" href="https://bit.ly/3yeDgkJ?li=locked/pharmacology-mobile-2" style=""><div class="title">Build, train, &amp; validate predictive machine-learning models with structured datasets.</div><div class="button-container"><div class="incopy-button btn btn-pink-filled">See how</div></div></a></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="associated-conditions">Associated Conditions</dt><dd class="col-xl-10 col-md-9 col-sm-8"><ul class="list-unstyled inline-list"><li><a href="/indications/DBCOND0060222">Constipation-predominant Irritable Bowel Syndrome (IBS-C)</a></li></ul></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="contraindications-blackbox-warnings">Contraindications &amp; Blackbox Warnings</dt><dd class="col-xl-10 col-md-9 col-sm-8"><a class="locked-incopy track-link" target="_blank" data-link-id="locked/contraindications-4" href="https://bit.ly/3l7in7x?li=locked/contraindications-4"><div class="incopy-left incopy-contraindications"><img class="locked-contraindications-img" src="/assets/locked/Contraindications-703de7931a118c8a7155ed9794980af9aab5ab60b4091bbf501e7524634ca922.png"><div class="incopy-text contraindications-text"><div class="title"><strong>Avoid life-threatening adverse drug events</strong></div><div class="subtitle">Improve clinical decision support with information on <strong>contraindications &amp; blackbox warnings, population restrictions, harmful risks, &amp; more.</strong></div></div></div><div class="incopy-button btn btn-pink-filled">Learn more<div class=" drugbank-icon icon-see_more"><svg class="icon" role="img" title="see_more"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#see_more"> </use></svg></div></div></a><a class="locked-incopy locked-incopy-mobile track-link" target="_blank" data-link-id="locked/contraindications-4" href="https://bit.ly/2US5HGY?li=locked/contraindications-4" style=""><div class="title">Avoid life-threatening adverse drug events &amp; improve clinical decision support.</div><div class="button-container"><div class="incopy-button btn btn-pink-filled">Learn more</div></div></a></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="pharmacodynamics">Pharmacodynamics</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>In general, it has been determined that tegaserod is an agonist of serotonin type-4 (5-HT(4)) receptors, an antagonist at 5-HT(2B) receptors, but is expected to possess minimal binding to 5-HT(1) receptors, and virtually no affinity for 5-HT(3) or dopamine receptors <sup class="text-reference-group"><a class="reference-popover-link" data-content="Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. (PubMed ID 15466450)" href="#reference-A11044" data-original-title="" title="">1</a>,<a class="reference-popover-link" data-content="Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, Sheldrick RL, Carey J, Coleman RA, Baxter GS: 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol. 2002 Mar;135(5):1144-51. doi: 10.1038/sj.bjp.0704571. (PubMed ID 11877320)" href="#reference-A176762" data-original-title="" title="">3</a>,<a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>In clinical trials with tegaserod, centrally analyzed ECGs were recorded in 4,605 male and female patients receiving tegaserod 6 mg twice daily or placebo for IBS-C and other related motility disorders <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. No subject receiving the agent had an absolute QTcF above 480 ms <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. An increase in QTcF of 30 to 60 ms was observed in 7% of patients receiving tegaserod and 8% receiving placebo <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. An increase in QTcF of greater than 60 ms was observed in 0.3% and 0.2% of subjects, respectively <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. The effects of tegaserod on the QTcF interval were ultimately not considered to be clinically meaningful <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>.</p>
<p>Furthermore, it was determined that there is a potential for tegaserod and its main metabolite (the M29 metabolite) to increase platelet aggregation in vitro <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. In one in vitro study, at concentrations up to 10-times the maximum plasma concentration (Cmax) at the recommended dose, tegaserod significantly increased platelet aggregation in a concentration-dependent manner up to 74% (range 11% to 74%) compared to a control vehicle (with potentiation by various agonists) <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. In another in vitro study, the M29 metabolite, at concentrations up to 0.6-times the Cmax of M29 also showed a 5% to 16% increase in platelet aggregation compared to the control vehicle <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. The clinical implications of these in vitro platelet aggregation results remain unclear <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>.</p>
</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="mechanism-of-action">Mechanism of action</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>Irritable bowel syndrome (IBS) is a complex functional disorder comprised of various abnormal and discomforting effects on the gastrointestinal tract and bowel function <sup class="text-reference-group"><a class="reference-popover-link" data-content="Talley NJ: Irritable bowel syndrome. Intern Med J. 2006 Nov;36(11):724-8. doi: 10.1111/j.1445-5994.2006.01217.x. (PubMed ID 17040359)" href="#reference-A176669" data-original-title="" title="">2</a>,<a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="EMA Refusal Assessment Report for Zelnorm (Tegaserod)" href="#reference-F4226" data-original-title="" title="">7</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. Although the cause of IBS has yet to be formally elucidated, patient experience has demonstrated that the disorder is typically associated with abdominal pain, abdominal distension, cramping or bloating, variations in urgency for bowel movements, feelings of incomplete evacuation, gastroesophageal reflux, and various other effects <sup class="text-reference-group"><a class="reference-popover-link" data-content="Talley NJ: Irritable bowel syndrome. Intern Med J. 2006 Nov;36(11):724-8. doi: 10.1111/j.1445-5994.2006.01217.x. (PubMed ID 17040359)" href="#reference-A176669" data-original-title="" title="">2</a>,<a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="EMA Refusal Assessment Report for Zelnorm (Tegaserod)" href="#reference-F4226" data-original-title="" title="">7</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. In particular, IBS that features constipation as a predominant effect is categorized as constipation-predominant IBS, or IBS-C <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>.</p>
<p>Concurrently, 5-Hydroxytryptamine (5-HT, or serotonin) has demonstrated the ability to elicit significant regulatory actions on gastrointestinal motility <sup class="text-reference-group"><a class="reference-popover-link" data-content="Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. (PubMed ID 15466450)" href="#reference-A11044" data-original-title="" title="">1</a></sup>. Specifically, it has been shown that the activation of 5-HT(4) receptors located on motor neurons and interneurons in the gastrointestinal wall can cause the release of acetylcholine, substance P, and calcitonin gene-related peptide that can all facilitate the propulsion of material through the gut <sup class="text-reference-group"><a class="reference-popover-link" data-content="Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. (PubMed ID 15466450)" href="#reference-A11044" data-original-title="" title="">1</a></sup>. Moreover, when 5-HT(4) receptors located in smooth muscle cells are also activated, activities that may alleviate symptoms of IBS-C like esophageal relaxation and the inhibition of human colonic circular muscle contraction can also occur <sup class="text-reference-group"><a class="reference-popover-link" data-content="Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. (PubMed ID 15466450)" href="#reference-A11044" data-original-title="" title="">1</a></sup>. Additionally, activating 5-HT(4) on enteric neurons and enterocytes also cause natural fluid secretion in the gut - an action which also strongly assists in promoting the movement of content along the gastrointestinal tract <sup class="text-reference-group"><a class="reference-popover-link" data-content="Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. (PubMed ID 15466450)" href="#reference-A11044" data-original-title="" title="">1</a></sup>.</p>
<p>Alternatively, it has also been observed that 5-HT may participate in generating visceral hyperalgesia in IBS, an observation supported in part by the finding of increased amounts of 5-HT and its metabolites in the plasma of patients experiencing IBS <sup class="text-reference-group"><a class="reference-popover-link" data-content="Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, Sheldrick RL, Carey J, Coleman RA, Baxter GS: 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol. 2002 Mar;135(5):1144-51. doi: 10.1038/sj.bjp.0704571. (PubMed ID 11877320)" href="#reference-A176762" data-original-title="" title="">3</a></sup> It has therefore also been proposed that antagonism of 5-HT(2B) receptors can lead to inhibition of both 5-HT mediated gastrointestinal motility and visceral hypersensitivity <sup class="text-reference-group"><a class="reference-popover-link" data-content="Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. (PubMed ID 15466450)" href="#reference-A11044" data-original-title="" title="">1</a></sup>.</p>
<p>Subsequently, because tegaserod is considered to be an agonist of the 5-HT(4) receptor and an antagonist of the 5-HT(2B) receptor at clinically relevant levels, it is believed that tegaserod may elicit its mechanism of action by facilitating activities associated with the activation and antagonism of the 5-HT(4) and 5-HT(2B) receptors, like stimulating peristaltic gastrointestinal reflexes and intestinal secretion, inhibiting visceral sensitivity, enhancing basal motor activity, and normalizing impaired motility throughout the gastrointestinal tract, among other actions <sup class="text-reference-group"><a class="reference-popover-link" data-content="Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. (PubMed ID 15466450)" href="#reference-A11044" data-original-title="" title="">1</a>,<a class="reference-popover-link" data-content="Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, Sheldrick RL, Carey J, Coleman RA, Baxter GS: 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol. 2002 Mar;135(5):1144-51. doi: 10.1038/sj.bjp.0704571. (PubMed ID 11877320)" href="#reference-A176762" data-original-title="" title="">3</a>,<a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="EMA Refusal Assessment Report for Zelnorm (Tegaserod)" href="#reference-F4226" data-original-title="" title="">7</a>,<a class="reference-popover-link" data-content="FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate)" href="#reference-F4229" data-original-title="" title="">8</a></sup>. </p>
<table class="table table-sm responsive-table" id="drug-moa-target-table"><thead><tr><th>Target</th><th>Actions</th><th>Organism</th></tr></thead><tbody><tr><td><span class="badge badge-pill badge-yes mr-2 tips" title="" data-original-title="Pharmacologically Active">A</span><a href="#BE0000084">5-hydroxytryptamine receptor 4</a></td><td><div class="badge badge-default">antagonist</div><div class="badge badge-default">partial agonist</div></td><td>Humans</td></tr><tr><td><span class="badge badge-pill badge-unknown mr-2 tips" title="" data-original-title="Pharmacological Action Unknown">U</span><a href="#BE0000393">5-hydroxytryptamine receptor 2B</a></td><td><div class="badge badge-default">antagonist</div></td><td>Humans</td></tr><tr><td><span class="badge badge-pill badge-unknown mr-2 tips" title="" data-original-title="Pharmacological Action Unknown">U</span><a href="#BE0000533">5-hydroxytryptamine receptor 2C</a></td><td><div class="badge badge-default">antagonist</div></td><td>Humans</td></tr><tr><td><span class="badge badge-pill badge-unknown mr-2 tips" title="" data-original-title="Pharmacological Action Unknown">U</span><a href="#BE0000451">5-hydroxytryptamine receptor 2A</a></td><td><div class="badge badge-default">antagonist</div></td><td>Humans</td></tr></tbody></table></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="absorption">Absorption</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>The absolute bioavailability of tegaserod is approximately 10% when administered to fasting subjects. The median time of peak tegaserod plasma concentration (Tmax) is approximately one hour (range 0.7 to 2 hours) <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>Nevertheless, when tegaserod was given to individuals thirty minutes before a meal of high-fat and high-calorie content (about 150 calories from protein, 250 calories from carbohydrates, and 500 calories from fat), the AUC was reduced by 40% to 65%, the Cmax was reduced by approximately 20% to 40%, and the median Tmax was 0.7 hours <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. Additionally, plasma concentrations were similar when tegaserod was administered within thirty minutes before a meal or even two and a half hours after a meal <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="volume-of-distribution">Volume of distribution</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>Although tegaserod is not approved for intravenous administration, data regarding the mean volume of distribution of tegaserod at steady-state is recorded as 368 ± 223 L following research of tegaserod administered intravenously <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="protein-binding">Protein binding</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>The protein binding recorded for tegaserod is about 98% <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="metabolism">Metabolism</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>Tegaserod is ultimately metabolized by way of hydrolysis and direct glucuronidation <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76. (PubMed ID 11560869)" href="#reference-A38972" data-original-title="" title="">4</a></sup>. The substance is firstly hydrolyzed in the stomach <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76. (PubMed ID 11560869)" href="#reference-A38972" data-original-title="" title="">4</a></sup>. It then undergoes oxidization and then conjugation to produce the main circulating tegaserod metabolite in human plasma, the so-called M29 metabolite, or 5-methoxyindole-3-carboxylic acid <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76. (PubMed ID 11560869)" href="#reference-A38972" data-original-title="" title="">4</a></sup>. Nevertheless, it has been determined that this main circulating metabolite has negligible affinity for 5-HT(4) receptors in vitro <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a>,<a class="reference-popover-link" data-content="Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76. (PubMed ID 11560869)" href="#reference-A38972" data-original-title="" title="">4</a></sup>. Furthermore, tegaserod can also experience direct N-glucuronidation at each of its three guanidine nitrogens which leads to the generation of three isomeric N-glucuronides - the so-called M43.2, M43.8, and M45.3 metabolites <sup class="text-reference-group"><a class="reference-popover-link" data-content="Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76. (PubMed ID 11560869)" href="#reference-A38972" data-original-title="" title="">4</a></sup>.</p>
<p class="d-none d-sm-block"><strong>Hover over products below to view reaction partners</strong></p><ul class="list-unstyled metabolite-pathway"><li><span class="metabolite" data-metabolite-id="1079">Tegaserod</span><ul class="list-unstyled"><li data-parent-id="1079"><div class="drugbank-icon icon-list-arrow"><svg class="icon" role="img" title="list-arrow">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#list-arrow"></use>
</svg>
</div><a class="metabolite" data-metabolite-id="2864" href="/reactions/3101">5-methoxyindole-3-carboxylic acid</a></li></ul></li></ul></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="route-of-elimination">Route of elimination</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>Approximately two-thirds of an orally administered dose of tegaserod is excreted unchanged in the feces, with the remaining one-third excreted in the urine as metabolites <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="half-life">Half-life</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>The mean terminal elimination half-life documented for tegaserod ranges from 4.6 to 8.1 hours following oral administration <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="clearance">Clearance</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>Although tegaserod is not approved for intravenous administration, data regarding the mean plasma clearance of tegaserod is documented as 77 ± 15 L/h following research of tegaserod administered intravenously <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="adverse-effects">Adverse Effects</dt><dd class="col-xl-10 col-md-9 col-sm-8"><a class="locked-incopy track-link" target="_blank" data-link-id="locked/adverse-effects-4" href="https://bit.ly/3rGqlWb?li=locked/adverse-effects-4"><div class="incopy-left incopy-adverseeffects"><img class="locked-adverseeffects-img" src="/assets/locked/AdverseEffects-37e38307d7a0e56f1351d8c6540669aa1ac302bb3a4d74e7b5b6ef7c4a95f515.png"><div class="incopy-text adverseeffects-text"><div class="title"><strong>Improve decision support &amp; research outcomes</strong></div><div class="subtitle">With structured adverse effects data, including: <strong>blackbox warnings, adverse reactions, warning &amp; precautions, &amp; incidence rates.</strong></div></div></div><div class="incopy-button btn btn-pink-filled">Learn more<div class=" drugbank-icon icon-see_more"><svg class="icon" role="img" title="see_more"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#see_more"> </use></svg></div></div></a><a class="locked-incopy locked-incopy-mobile track-link" target="_blank" data-link-id="locked/adverse-effects-4" href="https://bit.ly/2VkZH9d?li=locked/adverse-effects-4" style=""><div class="title">Improve decision support &amp; research outcomes with our structured adverse effects data.</div><div class="button-container"><div class="incopy-button btn btn-pink-filled">Learn more</div></div></a></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="toxicity">Toxicity</dt><dd class="col-xl-10 col-md-9 col-sm-8"><p>Single oral doses of 120 mg (which is 20 times the recommended dose) of tegaserod were administered to three healthy subjects in one study <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. All three subjects developed diarrhea and headache. Two of these subjects also reported intermittent abdominal pain and one developed orthostatic hypotension <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. In 28 healthy subjects exposed to 90 to 180 mg per day of tegaserod (which is 7.5 to 15 times the recommended daily dosage) for several days, adverse reactions were diarrhea (100%), headache (57%), abdominal pain (18%), flatulence (18%), nausea (7%), and vomiting (7%) <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>Although available data from case reports with tegaserod use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, animal studies involving maternal dietary administration of tegaserod with doses 45 to 71 times the recommended dose demonstrated decreased body weight, delays in developmental landmarks, and decreased survival in rat pups <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. Caution and careful consideration of risks versus benefits are recommended before administering tegaserod to a pregnant woman.</p>
<p>Despite there being little if any data available regarding the presence of tegaserod in human milk, the effects on the breastfed infant, or the effects on milk production, tegaserod and its metabolites are present in rat milk and the milk to plasma concentration ratio is very high in rats <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. Subsequently, because of the potential for serious reactions in the breastfed infant, including tumorigenicity, breastfeeding is not recommended during treatment with tegaserod <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>The safety and effectiveness of tegaserod in pediatric patients has not yet been established <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>Tegaserod is not indicated in patients that are aged 65 years or older <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>Tegaserod was not carcinogenic in rats given oral dietary doses up to 180 mg/kg/day (approximately 93 to 111 times the recommended dose based on AUC) for 110 to 124 weeks <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. In mice, dietary administration of tegaserod for 104 weeks produced mucosal hyperplasia and adenocarcinoma of the small intestine at 600 mg/kg/day (approximately 83 to 110 times the recommended dose based on AUC) <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. There was no evidence of carcinogenicity at lower doses (3 to 35 times the recommended dose based on AUC) <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. Tegaserod was not genotoxic in the in vitro Chinese hamster lung fibroblast (CHL/V79) cell chromosomal aberration and forward mutation test, the in vitro rat hepatocyte unscheduled DNA synthesis (UDS) test or the in vivo mouse micronucleus test <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. The results of the Ames test for mutagenicity were equivocal. Tegaserod at oral (dietary) doses up to 240 mg/kg/day (approximately 57 times the recommended dose based on AUC) in male rats and 150 mg/kg/day (approximately 42 times the recommended dose based on AUC) in female rats was found to have no effect on fertility and reproductive performance <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>Inhibition of the hERG (human Ether-a-go-go-Related Gene) channel was evident only in the micromolar concentration range with an IC50 of 13 micromolar (approximately 1300 times the Cmax in humans at the recommended dose) <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. In in vitro studies, tegaserod had no effects on impulse conduction in isolated guinea pig papillary muscle at up to 100 times the Cmax in humans, Langendorff-perfused isolated rabbit heart (QT interval) at up to 1000 times the Cmax in humans, or human atrial myocytes at multiples up to 10 times the Cmax in humans <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. The major metabolite, M29, had no effect on QT in the Langendorff-perfused isolated rabbit heart at multiples up to 323 times the Cmax in humans <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>In anesthetized and conscious dogs, tegaserod at doses up to 92 to 134 times the recommended dose based on Cmax did not alter heart rate, QRS interval duration, QTc or other ECG parameters <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. In chronic toxicology studies in rats and dogs, there were no treatment-related changes in cardiac morphology after tegaserod administration at doses up to 660 times the recommended dose based on AUC <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>Although tegaserod is expected to bind to 5-HT2B receptors in humans at the recommended dose, there does not appear to be any potential for heart valve injury based on functional evidence of 5-HT2B receptor antagonism <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>Studies with isolated coronary and mesenteric blood vessels from non-human primates and humans showed no vasoconstrictor effect at concentrations approximately 100 times the human Cmax <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. Tegaserod exhibited antagonism of 5-HT-mediated vasoconstriction via 5-HT1B receptors <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. In rat thoracic aortic rings that were pre-constricted with phenylephrine or norepinephrine, tegaserod produced vasorelaxation, with IC50 values 6 and 64 times the Cmax plasma concentrations in humans, respectively <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>. No effects were observed in the basal tone of aortic rings at concentrations up to 1000 times the human Cmax <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
<p>In studies with an anesthetized rat model for measuring macro- and micro-circulation of the colon, intraduodenal dosing with tegaserod (approximately 7 times the recommended dose based on Cmax) produced no clinically relevant effect on blood pressure, heart rate, or vascular conductance <sup class="text-reference-group"><a class="reference-popover-link" data-content="Tegaserod 2019 FDA Label" href="#reference-F4223" data-original-title="" title="">6</a></sup>.</p>
</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="pathways">Pathways</dt><dd class="col-xl-10 col-md-9 col-sm-8"><span class="not-available">Not Available</span></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="pharmacogenomic-effects-adrs">Pharmacogenomic Effects/ADRs <a tabindex="0" role="button" data-toggle="popover" data-content="SNP Mediated Pharmacological Effects and Adverse Drug Reactions (ADRs) is a compilation of drug-specific pharmacogenomic information from various sources and primary literature. — <a target=&quot;_blank&quot; href=&quot;/snp_actions&quot;>Browse all</a>" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);" data-original-title="About SNP Mediated Effects/ADRs"><div class="drugbank-icon icon-information"><svg class="icon" role="img" title="information">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#information"></use>
</svg>
</div></a></dt><dd class="col-xl-10 col-md-9 col-sm-8"><span class="not-available">Not Available</span></dd></dl><h2 id="interactions-header" class="section-header">Interactions</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4" id="drug-interactions">Drug Interactions <a tabindex="0" role="button" data-toggle="popover" data-content="Drug-drug interactions extracted from drug labels and scientific publications. The commercial version includes severity and basis for interaction. — <a target=&quot;_blank&quot; href=&quot;https://www.drugbank.com/scientific&quot;>Learn More</a>" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);" data-original-title="About Drug Interactions"><div class="drugbank-icon icon-information"><svg class="icon" role="img" title="information">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#information"></use>
</svg>
</div></a></dt><dd class="col-xl-10 col-md-9 col-sm-8"><div class="alert alert-danger">This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. </div><ul class="nav nav-tabs drug-interaction-tabs"><li class="interactions approved nav-item"><a class="toggle-row-display nav-link active" data-source="/drugs/DB01079/drug_interactions.json?group=approved" href="#show-approved">Approved</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link " data-source="/drugs/DB01079/drug_interactions.json?group=vet_approved" href="#show-vet_approved">Vet approved</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link " data-source="/drugs/DB01079/drug_interactions.json?group=nutraceutical" href="#show-nutraceutical">Nutraceutical</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link " data-source="/drugs/DB01079/drug_interactions.json?group=illicit" href="#show-illicit">Illicit</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link " data-source="/drugs/DB01079/drug_interactions.json?group=withdrawn" href="#show-withdrawn">Withdrawn</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link " data-source="/drugs/DB01079/drug_interactions.json?group=investigational" href="#show-investigational">Investigational</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link " data-source="/drugs/DB01079/drug_interactions.json?group=experimental" href="#show-experimental">Experimental</a></li><li class="interactions index nav-item"><a class="toggle-row-display nav-link" data-source="/drugs/DB01079/drug_interactions.json" href="#show-all">All Drugs</a></li></ul><div class="drug-interaction-table has-locked-panel"><table class="table table-sm dt-responsive datatable-remote" data-source="/drugs/DB01079/drug_interactions.json?group=approved" data-total="854" id="drug-interactions-table" style="width: 100%"><thead><tr><th class="head-sm">Drug</th><th>Interaction</th></tr><tr class="unlock-interactions-row"><th class="no-sort" colspan="2"><div class="locked-link" data-target="#locked-interactions-modal" data-toggle="modal">Integrate drug-drug <br>interactions in your software<div class="drugbank-icon icon-plus"><svg class="icon" role="img" title="plus">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#plus"></use>
</svg>
</div></div></th></tr></thead><tbody><tr><td><a href="/drugs/DB01281">Abatacept</a></td><td>The metabolism of Tegaserod can be increased when combined with Abatacept.</td></tr><tr><td><a href="/drugs/DB12001">Abemaciclib</a></td><td>Abemaciclib may decrease the excretion rate of Tegaserod which could result in a higher serum level.</td></tr><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>The metabolism of Tegaserod can be decreased when combined with Abiraterone.</td></tr><tr><td><a href="/drugs/DB14973">Abrocitinib</a></td><td>The serum concentration of Tegaserod can be increased when it is combined with Abrocitinib.</td></tr><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>The metabolism of Acebutolol can be decreased when combined with Tegaserod.</td></tr><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The metabolism of Acenocoumarol can be decreased when combined with Tegaserod.</td></tr><tr><td><a href="/drugs/DB00316">Acetaminophen</a></td><td>The metabolism of Acetaminophen can be decreased when combined with Tegaserod.</td></tr><tr><td><a href="/drugs/DB00819">Acetazolamide</a></td><td>The risk or severity of adverse effects can be increased when Acetazolamide is combined with Tegaserod.</td></tr><tr><td><a href="/drugs/DB08897">Aclidinium</a></td><td>The therapeutic efficacy of Tegaserod can be decreased when used in combination with Aclidinium.</td></tr><tr><td><a href="/drugs/DB00787">Acyclovir</a></td><td>The metabolism of Acyclovir can be decreased when combined with Tegaserod.</td></tr></tbody></table><div class="locked-panel-holder" data-for="#drug-interactions-table"><div class="locked-interactions-content"><img class="locked-interactions-img" src="/assets/locked/Interactions-a0b9baf74954e8e26155347c9fde26bca0898cecdb887b212605f778364855c2.png"><div class="locked-panel-header">Identify potential medication risks</div><div class="locked-panel-subheader">Easily compare up to 40 drugs with our drug interaction checker.</div><div class="locked-panel-subheader"><strong>Get severity rating, description, and management advice. </strong></div><a class="btn btn-pink-filled track-link" target="_blank" data-link-id="locked/drug-interactions-desktop-2" href="https://bit.ly/3iW94Vb?li=locked/drug-interactions-desktop-2">Learn more <div class=" drugbank-icon icon-see_more"><svg class="icon" role="img" title="see_more"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#see_more"> </use></svg></div></a></div></div></div></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="food-interactions">Food Interactions</dt><dd class="col-xl-10 col-md-9 col-sm-8"><ul class="list-unstyled table-list"><li>Take before a meal. To increase absorption, take 30 minutes before a meal.</li></ul></dd></dl><h2 id="products-header" class="section-header">Products</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4"></dt><dd class="col-xl-10 col-md-9 col-sm-8"><a class="locked-incopy track-link" target="_blank" data-link-id="locked/products-desktop-2" href="https://bit.ly/3jfwN2X?li=locked/products-desktop-2"><div class="incopy-left incopy-products2"><img class="locked-products2-img" src="/assets/locked/Products2-edc20e8268d35c9156660b16a7756bc2ba8eede8248449398cdfd75016ea3ade.png"><div class="incopy-text products2-text"><div class="title"><strong>Drug product information from 10+ global regions</strong></div><div class="subtitle">Our datasets provide approved product information including:<br><strong>dosage, form, labeller, route of administration, and marketing period.</strong></div></div></div><div class="incopy-button btn btn-pink-filled">Access now<div class=" drugbank-icon icon-see_more"><svg class="icon" role="img" title="see_more"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#see_more"> </use></svg></div></div></a><a class="locked-incopy locked-incopy-mobile track-link" target="_blank" data-link-id="locked/products-mobile-2" href="https://bit.ly/3rDRysG?li=locked/products-mobile-2" style=""><div class="title">Access drug product information from over 10 global regions.</div><div class="button-container"><div class="incopy-button btn btn-pink-filled">Access now</div></div></a></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="product-ingredients">Product Ingredients <a tabindex="0" role="button" data-toggle="popover" data-content="Active ingredients including salts and other forms of exact ingredients used in drug products." title="" id="product-ingredients-info" class="drug-info-popup" href="javascript:void(0);" data-original-title="About Product Ingredients"><div class="drugbank-icon icon-information"><svg class="icon" role="img" title="information">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#information"></use>
</svg>
</div></a></dt><dd class="col-xl-10 col-md-9 col-sm-8"><table class="table table-sm responsive-table" id="drug-salts-table"><thead><tr><th>Ingredient</th><th>UNII</th><th>CAS</th><th>InChI Key</th></tr></thead><tbody><tr><td><strong><a href="/salts/DBSALT001797">Tegaserod maleate</a></strong></td><td><a target="_blank" rel="noopener" href="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=E5XNT3RF5A">E5XNT3RF5A</a></td><td>189188-57-6</td><td class="break-cell">CPDDZSSEAVLMRY-FEQFWAPWSA-N</td></tr></tbody></table></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="international-other-brands">International/Other Brands</dt><dd class="col-xl-10 col-md-9 col-sm-8"><span class="separated-list-container"><span class="separated-list col-lg-12 col-xl-6"><span class="separated-list-item">Zelmac</span></span></span></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="brand-name-prescription-products">Brand Name Prescription Products</dt><dd class="col-xl-10 col-md-9 col-sm-8"><table class="products table table-sm dt-responsive datatable-remote" data-source="/drugs/DB01079/products.json?group=approved" data-total="5" id="approved-products" style="width: 100%"><thead><tr><th class="all">Name</th><th>Dosage</th><th>Strength</th><th class="all">Route</th><th>Labeller</th><th>Marketing Start</th><th>Marketing End</th><th><span class="hidden-title">Region</span></th><th class="drug-image"><span class="hidden-title">Image</span></th></tr></thead><tbody><tr><td>Zelnorm</td><td>Tablet</td><td>2 mg/1</td><td>Oral</td><td>Novartis</td><td>2002-07-24</td><td>2010-05-31</td><td><span class="country"><span hidden="hidden">US</span><img loading="lazy" title="US" alt="US flag" src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg"></span></td><td></td></tr><tr><td>Zelnorm</td><td>Tablet</td><td>6 mg/1</td><td>Oral</td><td>Novartis</td><td>2002-07-24</td><td>2009-01-31</td><td><span class="country"><span hidden="hidden">US</span><img loading="lazy" title="US" alt="US flag" src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg"></span></td><td></td></tr><tr><td>Zelnorm</td><td>Tablet</td><td>6 mg/1</td><td>Oral</td><td>Alfasigma USA, Inc.</td><td>2019-08-01</td><td><span class="not-available">Not applicable</span></td><td><span class="country"><span hidden="hidden">US</span><img loading="lazy" title="US" alt="US flag" src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg"></span></td><td></td></tr><tr><td>Zelnorm</td><td>Tablet</td><td>6 mg/1</td><td>Oral</td><td>Novartis</td><td>2002-07-24</td><td>2008-06-30</td><td><span class="country"><span hidden="hidden">US</span><img loading="lazy" title="US" alt="US flag" src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg"></span></td><td></td></tr><tr><td>Zelnorm</td><td>Tablet</td><td>6 mg/1</td><td>Oral</td><td>US WorldMeds, LLC</td><td>2019-07-29</td><td>2022-08-31</td><td><span class="country"><span hidden="hidden">US</span><img loading="lazy" title="US" alt="US flag" src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg"></span></td><td></td></tr></tbody></table></dd></dl><h2 id="categories-header" class="section-header">Categories</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4" id="atc-codes">ATC Codes</dt><dd class="col-xl-10 col-md-9 col-sm-8"><a data-no-turbolink="true" href="/atc/A06AX06">A06AX06 — Tegaserod</a><ul class="atc-drug-tree"><li><a data-no-turbolink="true" href="/atc/A06AX">A06AX — Other drugs for constipation</a></li><li><a data-no-turbolink="true" href="/atc/A06A">A06A — DRUGS FOR CONSTIPATION</a></li><li><a data-no-turbolink="true" href="/atc/A06">A06 — DRUGS FOR CONSTIPATION</a></li><li><a data-no-turbolink="true" href="/atc/A">A — ALIMENTARY TRACT AND METABOLISM</a></li></ul></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="drug-categories">Drug Categories</dt><dd class="col-xl-10 col-md-9 col-sm-8"><div class="category-columns"><ul class="list-unstyled table-list"><li><a href="/categories/DBCAT002118">Alimentary Tract and Metabolism</a></li>
<li><a href="/categories/DBCAT000345">Antidepressive Agents</a></li>
<li><a href="/categories/DBCAT002663">BCRP/ABCG2 Substrates</a></li>
<li><a href="/categories/DBCAT000399">Central Nervous System Depressants</a></li>
<li><a href="/categories/DBCAT000402">Cytochrome P-450 CYP1A2 Inhibitors</a></li>
<li><a href="/categories/DBCAT004503">Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)</a></li>
<li><a href="/categories/DBCAT000868">Cytochrome P-450 CYP2C8 Inhibitors</a></li>
<li><a href="/categories/DBCAT003042">Cytochrome P-450 CYP2C8 Inhibitors (weak)</a></li>
<li><a href="/categories/DBCAT000911">Cytochrome P-450 CYP2D6 Inhibitors</a></li>
<li><a href="/categories/DBCAT002625">Cytochrome P-450 CYP2D6 Inhibitors (moderate)</a></li>
<li><a href="/categories/DBCAT002623">Cytochrome P-450 CYP2D6 Substrates</a></li>
<li><a href="/categories/DBCAT002629">Cytochrome P-450 CYP2E1 Inhibitors</a></li>
<li><a href="/categories/DBCAT003036">Cytochrome P-450 CYP2E1 Inhibitors (weak)</a></li>
<li><a href="/categories/DBCAT000394">Cytochrome P-450 Enzyme Inhibitors</a></li>
<li><a href="/categories/DBCAT005101">Cytochrome P-450 Substrates</a></li>
<li><a href="/categories/DBCAT002415">Drugs for Constipation</a></li>
<li><a href="/categories/DBCAT000048">Gastrointestinal Agents</a></li>
<li><a href="/categories/DBCAT004973">Heterocyclic Compounds, Fused-Ring</a></li>
<li><a href="/categories/DBCAT001927">Laxatives</a></li>
<li><a href="/categories/DBCAT002668">P-glycoprotein substrates</a></li>
<li><a href="/categories/DBCAT003826">Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome</a></li>
<li><a href="/categories/DBCAT005477">Serotonin 4 Receptor Agonists</a></li>
<li><a href="/categories/DBCAT001320">Serotonin 5-HT2 Receptor Antagonists</a></li>
<li><a href="/categories/DBCAT005168">Serotonin 5-HT2A Receptor Antagonists</a></li>
<li><a href="/categories/DBCAT005169">Serotonin 5-HT2C Receptor Antagonists</a></li>
<li><a href="/categories/DBCAT000401">Serotonin Agents</a></li>
<li><a href="/categories/DBCAT000604">Serotonin Receptor Antagonists</a></li>
<li><a href="/categories/DBCAT005474">Serotonin-4 Receptor Agonist</a></li></ul></div></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="chemical-taxonomy">Chemical Taxonomy<span class="note">Provided by <a target="_blank" href="http://classyfire.wishartlab.com">Classyfire</a></span></dt><dd class="col-xl-10 col-md-9 col-sm-8"><dl class="inner-dl"><dt class="col-md-4 col-sm-5" id="description">Description</dt><dd class="col-md-8 col-sm-7">This compound belongs to the class of organic compounds known as indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene to form 2,3-benzopyrrole.</dd><dt class="col-md-4 col-sm-5" id="kingdom">Kingdom</dt><dd class="col-md-8 col-sm-7"><a class="classyfire-taxnode" data-content="Compounds that contain at least one carbon atom, excluding isocyanide/cyanide and their non-hydrocarbyl derivatives, thiophosgene, carbon diselenide, carbon monosulfide, carbon disulfide, carbon subsulfide, carbon monoxide, carbon dioxide, Carbon suboxide, and dicarbon monoxide." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000000" data-original-title="" title="">Organic compounds</a></dd><dt class="col-md-4 col-sm-5" id="super-class">Super Class</dt><dd class="col-md-8 col-sm-7"><a class="classyfire-taxnode" data-content="Compounds containing a ring with least one carbon atom and one non-carbon atom." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000002" data-original-title="" title="">Organoheterocyclic compounds</a></dd><dt class="col-md-4 col-sm-5" id="class">Class</dt><dd class="col-md-8 col-sm-7"><a class="classyfire-taxnode" data-content="Organic compounds containing an indole, which is a bicyclic ring system made up of a six-membered benzene ring fused to a five-membered nitrogen-containing pyrrole ring." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000211" data-original-title="" title="">Indoles and derivatives</a></dd><dt class="col-md-4 col-sm-5" id="sub-class">Sub Class</dt><dd class="col-md-8 col-sm-7"><a class="classyfire-taxnode" data-content="Compounds containing an indole moiety, which consists of pyrrole ring fused to benzene  to form 2,3-benzopyrrole." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0002497" data-original-title="" title="">Indoles</a></dd><dt class="col-md-4 col-sm-5" id="direct-parent">Direct Parent</dt><dd class="col-md-8 col-sm-7"><a class="classyfire-taxnode" data-content="Compounds containing an indole moiety, which consists of pyrrole ring fused to benzene  to form 2,3-benzopyrrole." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0002497" data-original-title="" title="">Indoles</a></dd><dt class="col-md-4 col-sm-5" id="alternative-parents">Alternative Parents</dt><dd class="col-md-8 col-sm-7"><span class="separated-list-container"><span class="separated-list col-lg-12 col-xl-6"><span class="separated-list-item"><a class="classyfire-taxnode" data-content="Organic compounds containing a methoxybenzene or a derivative thereof." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000138" data-original-title="" title="">Anisoles</a></span><span class="list-separator"> / </span><span class="separated-list-item"><a class="classyfire-taxnode" data-content="Organic compounds containing the alkyl aryl ether functional group with the generic formula R-O-R' , where R is an alkyl group and R' is an aryl group." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000128" data-original-title="" title="">Alkyl aryl ethers</a></span><span class="list-separator"> / </span><span class="separated-list-item"><a class="classyfire-taxnode" data-content="Heterocyclic compounds containing a pyrrole ring substituted at one or more positions." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0002257" data-original-title="" title="">Substituted pyrroles</a></span><span class="list-separator"> / </span><span class="separated-list-item"><a class="classyfire-taxnode" data-content="Compounds containing an aromatic ring where a carbon atom is linked to an hetero atom." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004144" data-original-title="" title="">Heteroaromatic compounds</a></span><span class="list-separator"> / </span><span class="separated-list-item"><a class="classyfire-taxnode" data-content="Compounds containing a guanidine moiety, with the general structure (R1R2N)(R3R4N)C=N-R5." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000375" data-original-title="" title="">Guanidines</a></span><span class="list-separator"> / </span><span class="separated-list-item"><a class="classyfire-taxnode" data-content="Organonitrogen compounds with the general formula RN=CN(R')(R''), (R,R',R'' = H or organyl group)." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0003152" data-original-title="" title="">Carboximidamides</a></span><span class="list-separator"> / </span><span class="separated-list-item"><a class="classyfire-taxnode" data-content="Organic compounds containing an heterocycle with at least one nitrogen atom and one carbon atom linked to each other." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004139" data-original-title="" title="">Azacyclic compounds</a></span><span class="list-separator"> / </span><span class="separated-list-item"><a class="classyfire-taxnode" data-content="Compounds containing a bond between carbon a pnictogen atom. Pnictogens are p-block element atoms that are in the group 15 of the periodic table." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004557" data-original-title="" title="">Organopnictogen compounds</a></span><span class="list-separator"> / </span><span class="separated-list-item"><a class="classyfire-taxnode" data-content="Compounds containing an imine functional group, with the general structure RN=CR2 (R = H, hydrocarbyl)." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000117" data-original-title="" title="">Imines</a></span><span class="list-separator"> / </span><span class="separated-list-item"><a class="classyfire-taxnode" data-content="Derivatives of hydrocarbons obtained by substituting one or more carbon atoms by an heteroatom. They contain at least one carbon atom and heteroatom." target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004150" data-original-title="" title="">Hydrocarbon derivatives</a></span></span></span></dd><dt class="col-md-4 col-sm-5" id="substituents">Substituents</dt><dd class="col-md-8 col-sm-7"><span class="separated-list-container"><span class="separated-list col-lg-12 col-xl-6"><span class="separated-list-item">Alkyl aryl ether</span><span class="list-separator"> / </span><span class="separated-list-item">Anisole</span><span class="list-separator"> / </span><span class="separated-list-item">Aromatic heteropolycyclic compound</span><span class="list-separator"> / </span><span class="separated-list-item">Azacycle</span><span class="list-separator"> / </span><span class="separated-list-item">Benzenoid</span><span class="list-separator"> / </span><span class="separated-list-item">Carboximidamide</span><span class="list-separator"> / </span><span class="separated-list-item">Ether</span><span class="list-separator"> / </span><span class="separated-list-item">Guanidine</span><span class="list-separator"> / </span><span class="separated-list-item">Heteroaromatic compound</span><span class="list-separator"> / </span><span class="separated-list-item">Hydrocarbon derivative</span></span></span></dd><dt class="col-md-4 col-sm-5" id="molecular-framework">Molecular Framework</dt><dd class="col-md-8 col-sm-7">Aromatic heteropolycyclic compounds</dd><dt class="col-md-4 col-sm-5" id="external-descriptors">External Descriptors</dt><dd class="col-md-8 col-sm-7"><span class="inline-separated-list-container"><span class="simple-separated-list-item">guanidines, indoles, carboxamidine, hydrazines (<a target="_blank" rel="noopener" href="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51043">CHEBI:51043</a>) </span></span></dd></dl></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="affected-organisms">Affected organisms</dt><dd class="col-xl-10 col-md-9 col-sm-8"><ul class="list-unstyled table-list"><li>Humans and other mammals</li></ul></dd></dl><h2 id="chemical-identifiers-header" class="section-header">Chemical Identifiers</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4" id="unii">UNII</dt><dd class="col-xl-10 col-md-9 col-sm-8"><a target="_blank" rel="noopener" href="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=458VC51857">458VC51857</a></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="cas-number">CAS number</dt><dd class="col-xl-10 col-md-9 col-sm-8">145158-71-0</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="inchi-key">InChI Key</dt><dd class="col-xl-10 col-md-9 col-sm-8">IKBKZGMPCYNSLU-RGVLZGJSSA-N</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="inchi">InChI</dt><dd class="col-xl-10 col-md-9 col-sm-8"><div class="wrap">InChI=1S/C16H23N5O/c1-3-4-5-8-18-16(17)21-20-11-12-10-19-15-7-6-13(22-2)9-14(12)15/h6-7,9-11,19H,3-5,8H2,1-2H3,(H3,17,18,21)/b20-11+</div></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="iupac-name">IUPAC Name</dt><dd class="col-xl-10 col-md-9 col-sm-8"><div class="wrap">N'-[(E)-[(5-methoxy-1H-indol-3-yl)methylidene]amino]-N-pentylguanidine</div></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="smiles">SMILES</dt><dd class="col-xl-10 col-md-9 col-sm-8"><div class="wrap">CCCCCNC(=N)N\N=C\C1=CNC2=C1C=C(OC)C=C2</div></dd></dl><h2 id="references-header" class="section-header">References</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4" id="synthesis-reference">Synthesis Reference</dt><dd class="col-xl-10 col-md-9 col-sm-8"><span class="citations"><p>Sundaram Venkataraman, Srinivasulu Gudipati, Brahmeshwararao Mandava Venkata Naga, Goverdhan Banda, Radhakrishna Singamsetty, "Process for preparing form I of tegaserod maleate." U.S. Patent US20050272802, issued December 08, 2005.</p>
</span><a target="_blank" rel="noopener" href="https://www.google.com/?tbm=pts#q=20050272802&amp;tbm=pts">US20050272802</a></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="general-references">General References</dt><dd class="col-xl-10 col-md-9 col-sm-8"><ol class="cite-this-references"><li id="reference-A11044">Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. [<a target="_blank" href="/articles/A11044">Article</a>] </li><li id="reference-A176669">Talley NJ: Irritable bowel syndrome. Intern Med J. 2006 Nov;36(11):724-8. doi: 10.1111/j.1445-5994.2006.01217.x. [<a target="_blank" href="/articles/A176669">Article</a>] </li><li id="reference-A176762">Borman RA, Tilford NS, Harmer DW, Day N, Ellis ES, Sheldrick RL, Carey J, Coleman RA, Baxter GS: 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol. 2002 Mar;135(5):1144-51. doi: 10.1038/sj.bjp.0704571. [<a target="_blank" href="/articles/A176762">Article</a>] </li><li id="reference-A38972">Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76. [<a target="_blank" href="/articles/A38972">Article</a>] </li><li id="reference-L5918">FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65 [<a target="_blank" href="https://www.erienewsnow.com/story/40228826/fda-approves-the-reintroduction-of-zelnorm-tegaserod-for-irritable-bowel-syndrome-with-constipation-ibs-c-in-women-under-65">Link</a>] </li><li id="reference-F4223">Tegaserod 2019 FDA Label [<a target="_blank" href="//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/223/original/021200Orig1s015lbl.pdf?1554242756">File</a>] </li><li id="reference-F4226">EMA Refusal Assessment Report for Zelnorm (Tegaserod) [<a target="_blank" href="//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/226/original/zelnorm-epar-refusal-public-assessment-report_en.pdf?1554245227">File</a>] </li><li id="reference-F4229">FDA Joint Meeting of the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Briefing Document for Zelnorm (tegaserod maleate) [<a target="_blank" href="//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/229/original/GIDAC-10172018-SloanBackgrounder.pdf?1554245700">File</a>] </li></ol></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="external-links">External Links</dt><dd class="col-xl-10 col-md-9 col-sm-8"><dl class="inner-dl"><dt class="col-md-4 col-sm-5" id="kegg-drug">KEGG Drug</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.genome.jp/dbget-bin/www_bget?drug:D06056">D06056</a></dd><dt class="col-md-4 col-sm-5" id="pubchem-compound">PubChem Compound</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5362436">5362436</a></dd><dt class="col-md-4 col-sm-5" id="pubchem-substance">PubChem Substance</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506519">46506519</a></dd><dt class="col-md-4 col-sm-5" id="chemspider">ChemSpider</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://www.chemspider.com/Chemical-Structure.10609889.html">10609889</a></dd><dt class="col-md-4 col-sm-5" id="bindingdb">BindingDB</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=79022">79022</a></dd><dt class="col-md-4 col-sm-5" id="rxnav">RxNav</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&amp;searchTerm=139778">139778</a></dd><dt class="col-md-4 col-sm-5" id="chebi">ChEBI</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=51043">51043</a></dd><dt class="col-md-4 col-sm-5" id="chembl">ChEMBL</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL76370">CHEMBL76370</a></dd><dt class="col-md-4 col-sm-5" id="zinc">ZINC</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://zinc.docking.org/substances/ZINC000001545565">ZINC000001545565</a></dd><dt class="col-md-4 col-sm-5" id="therapeutic-targets-database">Therapeutic Targets Database</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001526">DAP001526</a></dd><dt class="col-md-4 col-sm-5" id="pharmgkb">PharmGKB</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.pharmgkb.org/drug/PA130413154">PA130413154</a></dd><dt class="col-md-4 col-sm-5" id="rxlist">RxList</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.rxlist.com/cgi/generic3/zelnorm.htm">RxList Drug Page</a></dd><dt class="col-md-4 col-sm-5" id="drugs-com">Drugs.com</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://www.drugs.com/cdi/tegaserod.html">Drugs.com Drug Page</a></dd><dt class="col-md-4 col-sm-5" id="wikipedia">Wikipedia</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://en.wikipedia.org/wiki/Tegaserod">Tegaserod</a></dd></dl></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="fda-label">FDA label</dt><dd class="col-xl-10 col-md-9 col-sm-8"><div id="label-reference"><a href="//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01079.pdf?1265922812">Download</a> <span class="text-muted">(634 KB) </span></div></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="msds">MSDS</dt><dd class="col-xl-10 col-md-9 col-sm-8"><div id="msds-reference"><a href="//s3-us-west-2.amazonaws.com/drugbank/msds/DB01079.pdf?1265922748">Download</a> <span class="text-muted">(58.1 KB) </span></div></dd></dl><h2 id="clinical-trials-header" class="section-header">Clinical Trials</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4" id="clinical-trials">Clinical Trials <a tabindex="0" role="button" data-toggle="popover" data-content="Clinical trial data extracted from government clinical trial databases. The commercial version includes title, phase, status, dates, and conditions with associated ICD10 or MedDRA identifiers. — <a target=&quot;_blank&quot; href=&quot;https://www.drugbank.com/scientific&quot;>Learn More</a>" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);" data-original-title="About Clinical Trials"><div class="drugbank-icon icon-information"><svg class="icon" role="img" title="information">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#information"></use>
</svg>
</div></a></dt><dd class="col-xl-10 col-md-9 col-sm-8"><table class="clinical-trials table table-sm dt-responsive datatable-remote" data-source="/drugs/DB01079/clinical_trials/aggregate.json" data-total="18" style="width: 100%"><thead><tr><th>Phase</th><th>Status</th><th>Purpose</th><th>Conditions</th><th>Count</th></tr></thead><tbody><tr><td>4</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0031256">Chronic Constipation</a></td><td><a href="/drugs/DB01079/clinical_trials?conditions=DBCOND0031256&amp;phase=4&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>4</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0004520">Constipation</a></td><td><a href="/drugs/DB01079/clinical_trials?conditions=DBCOND0004520&amp;phase=4&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>4</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0031634">IBS-C and IBS With Mixed Bowel Habits</a></td><td><a href="/drugs/DB01079/clinical_trials?conditions=DBCOND0031634&amp;phase=4&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>4</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0031256">Chronic Constipation</a></td><td><a href="/drugs/DB01079/clinical_trials?conditions=DBCOND0031256&amp;phase=4&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>4</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0022048">Diabetes</a> <span>/</span> <a href="/indications/DBCOND0000847">Gastroparesis</a></td><td><a href="/drugs/DB01079/clinical_trials?conditions=DBCOND0022048%2CDBCOND0000847&amp;phase=4&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0031256">Chronic Constipation</a></td><td><a href="/drugs/DB01079/clinical_trials?conditions=DBCOND0031256&amp;phase=3&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0004520">Constipation</a></td><td><a href="/drugs/DB01079/clinical_trials?conditions=DBCOND0004520&amp;phase=3&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0004526">Dyspepsia</a></td><td><a href="/drugs/DB01079/clinical_trials?conditions=DBCOND0004526&amp;phase=3&amp;purpose=treatment&amp;status=completed">5</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0004526">Dyspepsia</a> <span>/</span> <a href="/indications/DBCOND0004515">Heartburn</a></td><td><a href="/drugs/DB01079/clinical_trials?conditions=DBCOND0004526%2CDBCOND0004515&amp;phase=3&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0077290">Gastro-esophageal Reflux Disease (GERD)</a></td><td><a href="/drugs/DB01079/clinical_trials?conditions=DBCOND0077290&amp;phase=3&amp;purpose=treatment&amp;status=completed">2</a></td></tr></tbody></table></dd></dl><h2 id="pharmacoeconomics-header" class="section-header">Pharmacoeconomics</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4" id="manufacturers">Manufacturers</dt><dd class="col-xl-10 col-md-9 col-sm-8"><div class="manufacturer-columns"><span class="not-available">Not Available</span></div></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="packagers">Packagers</dt><dd class="col-xl-10 col-md-9 col-sm-8"><div class="packager-columns"><ul class="list-unstyled table-list"><li>Murfreesboro Pharmaceutical Nursing Supply</li>
<li>Novartis AG</li></ul></div></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="dosage-forms">Dosage Forms</dt><dd class="col-xl-10 col-md-9 col-sm-8"><table class="table table-sm datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>2 mg/1</td></tr><tr><td>Tablet</td><td>Oral</td><td>6 mg/1</td></tr></tbody></table></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="prices">Prices</dt><dd class="col-xl-10 col-md-9 col-sm-8"><span class="not-available">Not Available</span></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="patents">Patents</dt><dd class="col-xl-10 col-md-9 col-sm-8"><table class="table table-sm datatable dt-responsive" id="patents" style="width: 100%"><thead><tr><th>Patent Number</th><th>Pediatric Extension</th><th>Approved</th><th>Expires (estimated)</th><th><span class="hidden-title">Region</span></th></tr></thead><tbody><tr><td><a target="_blank" rel="noopener" href="https://patents.google.com/patent/US5510353">US5510353</a></td><td><span class="badge badge-secondary badge-pill ">No</span></td><td>1996-04-23</td><td>2013-04-26</td><td class="country"><span class="country"><span hidden="hidden">US</span><img loading="lazy" title="US" alt="US flag" src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg"></span></td></tr></tbody></table></dd></dl><h2 id="properties-header" class="section-header">Properties</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4" id="state">State</dt><dd class="col-xl-10 col-md-9 col-sm-8">Solid</dd><dt class="col-xl-2 col-md-3 col-sm-4" id="experimental-properties">Experimental Properties</dt><dd class="col-xl-10 col-md-9 col-sm-8"><table class="table table-sm table-bordered" id="experimental-properties"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>melting point (°C)</td><td>155 °C</td><td><span class="not-available">Not Available</span></td></tr><tr><td>logP</td><td>2.6</td><td><span class="not-available">Not Available</span></td></tr></tbody></table></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="predicted-properties">Predicted Properties</dt><dd class="col-xl-10 col-md-9 col-sm-8"><table class="table table-sm responsive-table" id="drug-moldb-properties"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>Water Solubility</td><td>0.0288 mg/mL</td><td><a target="_blank" rel="noopener" href="http://www.vcclab.org/lab/alogps/">ALOGPS</a></td></tr><tr><td>logP</td><td>2.76</td><td><a target="_blank" rel="noopener" href="http://www.vcclab.org/lab/alogps/">ALOGPS</a></td></tr><tr><td>logP</td><td>2.95</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4</td><td><a target="_blank" rel="noopener" href="http://www.vcclab.org/lab/alogps/">ALOGPS</a></td></tr><tr><td>pKa (Strongest Acidic)</td><td>15.24</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (Strongest Basic)</td><td>8.5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>Physiological Charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>Hydrogen Acceptor Count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>Hydrogen Donor Count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>Polar Surface Area</td><td>85.29 Å<sup>2</sup></td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>Rotatable Bond Count</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>Refractivity</td><td>110.25 m<sup>3</sup>·mol<sup>-1</sup></td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>Polarizability</td><td>34.96 Å<sup>3</sup></td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Number of Rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>Bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Rule of Five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose Filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's Rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like Rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="predicted-admet-features">Predicted ADMET Features</dt><dd class="col-xl-10 col-md-9 col-sm-8"><table class="table table-sm responsive-table" id="drug-predicted-admet"><thead><tr><th>Property</th><th>Value</th><th>Probability</th></tr></thead><tbody><tr><td>Human Intestinal Absorption</td><td>+</td><td>0.9973</td></tr><tr><td>Blood Brain Barrier</td><td>+</td><td>0.7842</td></tr><tr><td>Caco-2 permeable</td><td>-</td><td>0.5939</td></tr><tr><td>P-glycoprotein substrate</td><td>Substrate</td><td>0.921</td></tr><tr><td>P-glycoprotein inhibitor I</td><td>Non-inhibitor</td><td>0.8978</td></tr><tr><td>P-glycoprotein inhibitor II</td><td>Non-inhibitor</td><td>0.959</td></tr><tr><td>Renal organic cation transporter</td><td>Inhibitor</td><td>0.5488</td></tr><tr><td>CYP450 2C9 substrate</td><td>Non-substrate</td><td>0.8522</td></tr><tr><td>CYP450 2D6 substrate</td><td>Non-substrate</td><td>0.5492</td></tr><tr><td>CYP450 3A4 substrate</td><td>Non-substrate</td><td>0.6565</td></tr><tr><td>CYP450 1A2 substrate</td><td>Non-inhibitor</td><td>0.53</td></tr><tr><td>CYP450 2C9 inhibitor</td><td>Non-inhibitor</td><td>0.7096</td></tr><tr><td>CYP450 2D6 inhibitor</td><td>Non-inhibitor</td><td>0.7807</td></tr><tr><td>CYP450 2C19 inhibitor</td><td>Non-inhibitor</td><td>0.6372</td></tr><tr><td>CYP450 3A4 inhibitor</td><td>Non-inhibitor</td><td>0.8954</td></tr><tr><td>CYP450 inhibitory promiscuity</td><td>Low CYP Inhibitory Promiscuity</td><td>0.7654</td></tr><tr><td>Ames test</td><td>Non AMES toxic</td><td>0.5434</td></tr><tr><td>Carcinogenicity</td><td>Non-carcinogens</td><td>0.7783</td></tr><tr><td>Biodegradation</td><td>Not ready biodegradable</td><td>0.9972</td></tr><tr><td>Rat acute toxicity</td><td>2.6038 LD50, mol/kg </td><td><span class="not-available">Not applicable</span></td></tr><tr><td>hERG inhibition (predictor I)</td><td>Weak inhibitor</td><td>0.5123</td></tr><tr><td>hERG inhibition (predictor II)</td><td>Non-inhibitor</td><td>0.8334</td></tr></tbody></table><div class="alert alert-warning clearfix admetsar-alert"><span class="glyphicon glyphicon-info-sign"> </span> ADMET data is predicted using <a href="http://lmmd.ecust.edu.cn:8000">admetSAR</a>, a free tool for evaluating chemical ADMET properties. (<a target="_blank" rel="noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/23092397">23092397</a>) </div></dd></dl><h2 id="spectra-header" class="section-header">Spectra</h2><dl><dt class="col-xl-2 col-md-3 col-sm-4" id="mass-spec">Mass Spec (NIST)</dt><dd class="col-xl-10 col-md-9 col-sm-8"><span class="not-available">Not Available</span></dd><dt class="col-xl-2 col-md-3 col-sm-4" id="spectra">Spectra</dt><dd class="col-xl-10 col-md-9 col-sm-8"><table class="table table-sm responsive-table" id="spectra-table"><thead><tr><th>Spectrum</th><th>Spectrum Type</th><th><a target="_blank" rel="noopener" href="http://splash.fiehnlab.ucdavis.edu/">Splash Key</a></th></tr></thead><tbody data-no-turbolink=""><tr><td><a href="/spectra/ms_ms/100248">Predicted MS/MS Spectrum - 10V, Positive (Annotated)</a></td><td>Predicted LC-MS/MS</td><td class="break-cell"><span class="not-available">Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/100249">Predicted MS/MS Spectrum - 20V, Positive (Annotated)</a></td><td>Predicted LC-MS/MS</td><td class="break-cell"><span class="not-available">Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/100250">Predicted MS/MS Spectrum - 40V, Positive (Annotated)</a></td><td>Predicted LC-MS/MS</td><td class="break-cell"><span class="not-available">Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/165516">Predicted MS/MS Spectrum - 10V, Negative (Annotated)</a></td><td>Predicted LC-MS/MS</td><td class="break-cell"><span class="not-available">Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/165517">Predicted MS/MS Spectrum - 20V, Negative (Annotated)</a></td><td>Predicted LC-MS/MS</td><td class="break-cell"><span class="not-available">Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/165518">Predicted MS/MS Spectrum - 40V, Negative (Annotated)</a></td><td>Predicted LC-MS/MS</td><td class="break-cell"><span class="not-available">Not Available</span></td></tr></tbody></table></dd></dl><div class="bond-list-container targets" id="targets"><h3>Targets</h3><div class="bond-list"><a class="locked-incopy track-link" target="_blank" data-link-id="locked/drug-targets-desktop-2" href="https://bit.ly/3iYePSn?li=locked/drug-targets-desktop-2"><div class="incopy-left incopy-drugtargets2"><img class="locked-drugtargets2-img" src="/assets/locked/DrugTargets2-682eb846d210ae4bf33ca03febccfb57bb1c61318e699b729e5df4dfab2c5b67.png"><div class="incopy-text drugtargets2-text"><div class="title"><strong>Build, predict &amp; validate machine-learning models</strong></div><div class="subtitle">Use our structured and evidence-based datasets to <strong>unlock new<br>insights and accelerate drug research.</strong></div></div></div><div class="incopy-button btn btn-pink-filled">Learn more<div class=" drugbank-icon icon-see_more"><svg class="icon" role="img" title="see_more"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#see_more"> </use></svg></div></div></a><a class="locked-incopy locked-incopy-mobile track-link" target="_blank" data-link-id="locked/drug-targets-mobile-2" href="https://bit.ly/3zOIrse?li=locked/drug-targets-mobile-2" style=""><div class="title">Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.</div><div class="button-container"><div class="incopy-button btn btn-pink-filled">Learn more</div></div></a><div class="bond card" id="BE0000084"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/Q13639"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>1. <a href="/polypeptides/Q13639">5-hydroxytryptamine receptor 4</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-yes">Yes</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Antagonist</div><div class="badge badge-pill badge-action">Partial agonist</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Serotonin receptor activity</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">HTR4</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/Q13639">Q13639</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">5-hydroxytryptamine receptor 4</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">43760.975 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A11041">Camilleri M: Review article: tegaserod. Aliment Pharmacol Ther. 2001 Mar;15(3):277-89. [<a target="_blank" href="/articles/A11041">Article</a>] </li><li id="reference-A11042">Kamm MA: Review article: the complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther. 2002 Mar;16(3):343-51. [<a target="_blank" href="/articles/A11042">Article</a>] </li><li id="reference-A11043">Corsetti M, Tack J: Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome. Expert Opin Pharmacother. 2002 Aug;3(8):1211-8. [<a target="_blank" href="/articles/A11043">Article</a>] </li><li id="reference-A11044">Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. [<a target="_blank" href="/articles/A11044">Article</a>] </li><li id="reference-A11045">Cole P, Rabasseda X: Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome. Drugs Today (Barc). 2004 Dec;40(12):1013-30. [<a target="_blank" href="/articles/A11045">Article</a>] </li><li id="reference-A9">Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [<a target="_blank" href="/articles/A9">Article</a>] </li></ol></div></div></div><div class="bond card" id="BE0000393"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P41595"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>2. <a href="/polypeptides/P41595">5-hydroxytryptamine receptor 2B</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Antagonist</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Serotonin receptor activity</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">HTR2B</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P41595">P41595</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">5-hydroxytryptamine receptor 2B</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">54297.41 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A11044">Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. [<a target="_blank" href="/articles/A11044">Article</a>] </li><li id="reference-A12380">McCullough JL, Armstrong SR, Hegde SS, Beattie DT: The 5-HT2B antagonist and 5-HT4 agonist activities of tegaserod in the anaesthetized rat. Pharmacol Res. 2006 Apr;53(4):353-8. Epub 2006 Feb 21. [<a target="_blank" href="/articles/A12380">Article</a>] </li><li id="reference-A12381">Greenwood-Van Meerveld B, Campbell-Dittmeyer K, Johnson AC, Hicks GA: 5-HT2B receptors do not modulate sensitivity to colonic distension in rats with acute colorectal hypersensitivity. Neurogastroenterol Motil. 2006 May;18(5):343-5. [<a target="_blank" href="/articles/A12381">Article</a>] </li></ol></div></div></div><div class="bond card" id="BE0000533"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P28335"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>3. <a href="/polypeptides/P28335">5-hydroxytryptamine receptor 2C</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Antagonist</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Serotonin receptor activity</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">HTR2C</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P28335">P28335</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">5-hydroxytryptamine receptor 2C</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">51820.705 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A11044">Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. [<a target="_blank" href="/articles/A11044">Article</a>] </li></ol></div></div></div><div class="bond card" id="BE0000451"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P28223"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>4. <a href="/polypeptides/P28223">5-hydroxytryptamine receptor 2A</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Antagonist</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Virus receptor activity</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">HTR2A</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P28223">P28223</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">5-hydroxytryptamine receptor 2A</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">52602.58 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A11044">Beattie DT, Smith JA, Marquess D, Vickery RG, Armstrong SR, Pulido-Rios T, McCullough JL, Sandlund C, Richardson C, Mai N, Humphrey PP: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. [<a target="_blank" href="/articles/A11044">Article</a>] </li></ol></div></div></div></div></div><div class="bond-list-container enzymes" id="enzymes"><h3>Enzymes</h3><div class="bond-list"><div class="bond card" id="BE0002433"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P05177"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>1. <a href="/polypeptides/P05177">Cytochrome P450 1A2</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Inhibitor</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">CYP1A2</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P05177">P05177</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Cytochrome P450 1A2</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">58293.76 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A39118">Zhou H, Khalilieh S, Svendsen K, Pommier F, Osborne S, Appel-Dingemanse S, Lasseter K, McLeod JF: Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects. J Clin Pharmacol. 2001 Sep;41(9):987-93. [<a target="_blank" href="/articles/A39118">Article</a>] </li><li id="reference-A38972">Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76. [<a target="_blank" href="/articles/A38972">Article</a>] </li></ol></div></div></div><div class="bond card" id="BE0002887"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P10632"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>2. <a href="/polypeptides/P10632">Cytochrome P450 2C8</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Inhibitor</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Steroid hydroxylase activity</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">CYP2C8</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P10632">P10632</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Cytochrome P450 2C8</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">55824.275 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A38112">Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [<a target="_blank" href="/articles/A38112">Article</a>] </li><li id="reference-A38972">Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76. [<a target="_blank" href="/articles/A38972">Article</a>] </li></ol></div></div></div><div class="bond card" id="BE0002363"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P10635"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>3. <a href="/polypeptides/P10635">Cytochrome P450 2D6</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Substrate</div><div class="badge badge-pill badge-action">Inhibitor</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Steroid hydroxylase activity</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">CYP2D6</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P10635">P10635</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Cytochrome P450 2D6</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">55768.94 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A38972">Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76. [<a target="_blank" href="/articles/A38972">Article</a>] </li></ol></div></div></div><div class="bond card" id="BE0003533"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P05181"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>4. <a href="/polypeptides/P05181">Cytochrome P450 2E1</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Inhibitor</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Steroid hydroxylase activity</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">CYP2E1</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P05181">P05181</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Cytochrome P450 2E1</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">56848.42 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A38972">Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76. [<a target="_blank" href="/articles/A38972">Article</a>] </li></ol></div></div></div></div></div><div class="bond-list-container transporters" id="transporters"><h3>Transporters</h3><div class="bond-list"><div class="bond card" id="BE0000749"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P31645"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>1. <a href="/polypeptides/P31645">Sodium-dependent serotonin transporter</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Substrate</div><div class="badge badge-pill badge-action">Inhibitor</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Serotonin:sodium symporter activity</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">SLC6A4</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P31645">P31645</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Sodium-dependent serotonin transporter</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">70324.165 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A16725">Ismair MG, Kullak-Ublick GA, Blakely RD, Fried M, Vavricka SR: Tegaserod inhibits the serotonin transporter SERT. Digestion. 2007;75(2-3):90-5. Epub 2007 May 18. [<a target="_blank" href="/articles/A16725">Article</a>] </li></ol></div></div></div><div class="bond card" id="BE0001067"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/Q9UNQ0"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>2. <a href="/polypeptides/Q9UNQ0">ATP-binding cassette sub-family G member 2</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Substrate</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Xenobiotic-transporting atpase activity</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">ABCG2</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/Q9UNQ0">Q9UNQ0</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">ATP-binding cassette sub-family G member 2</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">72313.47 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-F4223">Tegaserod 2019 FDA Label [<a target="_blank" href="//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/223/original/021200Orig1s015lbl.pdf?1554242756">File</a>] </li></ol></div></div></div><div class="bond card" id="BE0001032"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P08183"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#expand"></use>
</svg>
</div> Details</a><strong>3. <a href="/polypeptides/P08183">P-glycoprotein 1</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6" id="kind">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6" id="organism">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6" id="pharmacological-action">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6" id="actions">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Substrate</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6" id="general-function">General Function</dt><dd class="col-md-7 col-sm-6">Xenobiotic-transporting atpase activity</dd><dt class="col-md-5 col-sm-6" id="specific-function">Specific Function</dt><dd class="col-md-7 col-sm-6">Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</dd><dt class="col-md-5 col-sm-6" id="gene-name">Gene Name</dt><dd class="col-md-7 col-sm-6">ABCB1</dd><dt class="col-md-5 col-sm-6" id="uniprot-id">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P08183">P08183</a></dd><dt class="col-md-5 col-sm-6" id="uniprot-name">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Multidrug resistance protein 1</dd><dt class="col-md-5 col-sm-6" id="molecular-weight">Molecular Weight</dt><dd class="col-md-7 col-sm-6">141477.255 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-F4223">Tegaserod 2019 FDA Label [<a target="_blank" href="//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/223/original/021200Orig1s015lbl.pdf?1554242756">File</a>] </li></ol></div></div></div></div></div><div aria-hidden="true" aria-labelledby="locked-modal-header" class="modal fade" id="locked-interactions-modal" role="dialog" tabindex="-1"><div class="modal-dialog modal-dialog-centered"><div class="modal-content"><div class="modal-body"><button aria-hidden="true" class="close" data-dismiss="modal" type="button">×</button><div class="locked-interactions-content"><img class="locked-interactions-img" src="/assets/locked/Interactions-a0b9baf74954e8e26155347c9fde26bca0898cecdb887b212605f778364855c2.png"><div class="locked-panel-header">Identify potential medication risks</div><div class="locked-panel-subheader">Easily compare up to 40 drugs with our drug interaction checker.</div><div class="locked-panel-subheader"><strong>Get severity rating, description, and management advice. </strong></div><a class="btn btn-pink-filled track-link" target="_blank" data-link-id="locked/drug-interactions-mobile-2" href="https://bit.ly/2TFmz2P?li=locked/drug-interactions-mobile-2">Learn more <div class=" drugbank-icon icon-see_more"><svg class="icon" role="img" title="see_more"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#see_more"> </use></svg></div></a></div></div></div></div></div><p class="bt-2 px-sm-0" id="drug-meta">Drug created at June 13, 2005 13:24 / Updated at May 07, 2021 21:22 </p></div><div aria-hidden="true" aria-labelledby="package-image" class="modal fade" id="modal-package" role="dialog" tabindex="-1"><div class="modal-dialog modal-dialog-centered"><div class="modal-content"><div class="modal-header"><h4 class="modal-title">Product Image</h4><button aria-hidden="true" class="close" data-dismiss="modal" type="button">×</button></div><div class="modal-body"><img class="img-thumbnail modal-package-picture mb-4" src=""><a class="full-image float-right btn btn-drugbank-primary btn-sm mt-2" href="">Show full image</a><div class="package-description"></div></div></div></div></div></div></div></div></main><footer><div class="row p-3 p-sm-4 m-0"><div class="col-md-5 footer-content"><div class="footer-item footer-commercial hidden"><img style="width: 130px; height: 100px;" src="/assets/plus/Data_Pink-68da9b7525141f098e2e0ebcbd888ce950fe6032fd0da3a227c22117cedd7062.png"><h2>Interested in using DrugBank in a <strong>commercial product</strong> or <strong>application?</strong></h2><a class="btn btn-pink-filled" target="_blank" href="https://www.drugbank.com/">Visit DrugBank.com <div class=" drugbank-icon icon-see_more"><svg class="icon" role="img" title="see_more"> <use xlink:href="/assets/plus/icons-70333afa0729472c7516e40340ba51254bb889e8a9a12dcd9b4434a43b7ee583.svg#see_more"> </use></svg></div></a></div><div class="footer-item footer-newsletter" id="newsletter-1"><div class="newsletter-header"><img style="width: 131px; height: 100px;" src="/assets/plus/Article_Dark_Pink-17ef3dc892e28e001abbb0ae6bfc47fca8a64cd76af37ec2a80dbce89fe3bc72.png"><h2>Stay up-to-date with the <br><strong>latest from DrugBank!</strong></h2></div><form action="https://dev.drugbank.com/contacts" class="form" id="newsletter-form" method="post"><input class="form-control hidden" id="contact_name" name="contact[name]" type="hidden" value="New Subscriber"><input class="form-control hidden" id="contact_mailing_list" name="contact[mailing_list]" type="hidden" value="yes"><input class="form-control hidden" id="data_type" name="data_type" type="hidden" value="json"><input class="form-control hidden" id="contact_address" name="contact[address]" type="hidden"><input class="form-control hidden" name="contact[return_url]" type="hidden" value="https://go.drugbank.com/#newsletter-3"><input class="form-control hidden" name="contact[form_url]" type="hidden" value="https://go.drugbank.com/"><input class="form-control hidden" id="referer" name="contact[referer]" type="hidden" value=""><input class="form-control hidden" id="type" name="contact[type]" type="hidden" value="newsletter"><input class="form-control hidden" id="ga_client_id" name="contact[ga_client_id]" type="hidden" value="243346760.1646930944"><div class="input-group"><input class="form-control" id="contact_email" name="contact[email]" placeholder="Enter your email" required="" type="text"><span class="input-group-btn"><button class="btn btn-pink-filled" id="subscribe" type="submit">Subscribe</button></span></div><div class="help-block with-errors"></div></form></div><div class="footer-item footer-newsletter hidden" id="newsletter-3"><div class="newsletter-header"><img style="width: 131px; height: 100px;" src="/assets/plus/Article_Dark_Pink-17ef3dc892e28e001abbb0ae6bfc47fca8a64cd76af37ec2a80dbce89fe3bc72.png"><h2><strong>Thank you</strong> <br>for subscribing!</h2></div></div></div><div class="col-md-7 footer-links"><div class="container"><div class="row footer-row"><div class="col-sm-4 footer-col"><div class="footer-header">About</div><div class="footer-list"><ul class="list-unstyled"><li><a href="/about">About DrugBank Online</a></li><li><a target="_blank" href="https://blog.drugbank.com/">Blog</a></li><li><a target="_blank" href="http://www.wishartlab.com">Wishart Research Group</a></li><li><a href="https://www.drugbank.com/about/careers">Careers</a></li><li><a href="/legal/terms_of_use">Terms of Use</a></li><li><a href="/legal/privacy_policy">Privacy Policy</a></li></ul></div></div><div class="col-sm-4 footer-col"><div class="footer-header">Support</div><div class="footer-list"><ul class="list-unstyled"><li><a target="_blank" href="https://dev.drugbank.com/guides/index">Help Center</a></li><li><a target="_blank" href="https://dev.drugbank.com/guides/faqs">DrugBank Online FAQs</a></li><li><a href="/contact">Contact Support</a></li></ul></div></div><div class="col-sm-4 footer-col"><div class="footer-header"><a href="https://www.drugbank.com/">Products</a></div><div class="footer-list"><ul class="list-unstyled"><li><a target="_blank" href="https://www.drugbank.com/datasets">Commercial Drug Datasets</a></li><li><a target="_blank" href="https://www.drugbank.com/academic_research">Academic Drug Datasets</a></li><li><a target="_blank" href="https://www.drugbank.com/clinical">Clinical API</a></li><li><a target="_blank" href="https://www.drugbank.com/contact/sales?ref=go.drugbank.com%2Fdrugs%2FDB01079">Contact Sales</a></li></ul></div></div></div><div class="row footer-row"><div class="col-sm-12"><div class="social-media"><a class="social-media-link" href="https://www.linkedin.com/company/drugbank/"><div class="drugbank-icon icon-linkedin"><svg class="icon" role="img" title="linkedin">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#linkedin"></use>
</svg>
</div></a><a class="social-media-link" href="https://twitter.com/DrugBankDB"><div class="drugbank-icon icon-twitter"><svg class="icon" role="img" title="twitter">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#twitter"></use>
</svg>
</div></a><a class="social-media-link" href="https://www.facebook.com/DrugBankDatabase"><div class="drugbank-icon icon-facebook"><svg class="icon" role="img" title="facebook">
<use xlink:href="/assets/icons-539be351b538129271b9ee92cb0ebbd16efad4fccf6e2fe95aa6234f1e7417fa.svg#facebook"></use>
</svg>
</div></a></div><h6>Website design by Educe Design &amp; Innovation Inc.</h6></div></div></div></div></div></footer><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/v652eace1692a40cfa3763df669d7439c1639079717194" integrity="sha512-Gi7xpJR8tSkrpF7aordPZQlW2DLtzUlZcumS8dMQjwDHEnw9I7ZLyiOj/6tZStRBGtGgN6ceN6cMH8z7etPGlw==" data-cf-beacon="{&quot;rayId&quot;:&quot;6e9d8a9d1bfd35d7&quot;,&quot;token&quot;:&quot;e28ec36f07f74c1ca13c169ca4430981&quot;,&quot;version&quot;:&quot;2021.12.0&quot;,&quot;si&quot;:100}" crossorigin="anonymous"></script>
<script src="/assets/analytics-1b5960c76af2e5f1a83c45e21ee367baf13121e0a2d42380a71abadf0edaa402.js" media="all" data-turbolinks-track="true"></script><script type="text/javascript" id="hs-script-loader" async="" defer="" src="//js.hs-scripts.com/2224137.js"></script></body></html>